zileuton has been researched along with hydroxyurea in 375 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 160 (42.67) | 18.2507 |
| 2000's | 109 (29.07) | 29.6817 |
| 2010's | 88 (23.47) | 24.3611 |
| 2020's | 18 (4.80) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Clement, B; Indorf, P; Kubitza, C; Kunze, T; Scheidig, AJ | 1 |
| Chamulitrat, W; Mason, RP; Riendeau, D | 1 |
| Grisham, MB; Keenan, CM; Vaananen, PM; Wallace, JL | 1 |
| Abraham, WM; Ahmed, A; Bell, RL; Bouska, J; Cortes, A; Hinz, W; Lanni, C; Sielczak, MW | 1 |
| Coblyn, JS; Helfgott, S; Henson, B; Kremer, JM; Maier, AL; Petrillo, G; Rubin, P; Sperling, R; Weinblatt, ME | 1 |
| Crawley, GC; Foster, SJ; McMillan, RM; Spruce, KE; Walker, ER | 1 |
| Desai, SN; Jamieson-Leclercq, T; Noonan, TC | 1 |
| Henson, PM; Hill, E; Maclouf, J; Murphy, RC | 1 |
| Alvarez, FJ; Slade, RT | 1 |
| Bobadilla, J; Borovoy, J; Cabrera, G; Collawn, C; Kershenobich, D; Perez, N; Reyes, E; Rubin, P | 1 |
| Albert, D; Bell, RL; Brooks, DW; Carter, GW; Lanni, C; Rubin, P; Summers, JB; Young, PR | 1 |
| Nellans, HN; Sweeny, DJ | 2 |
| Chan, CC; Foster, A; Guay, J; Riendeau, D; Wolfe, S | 1 |
| Borgeat, P; Dubé, L; Kesterson, J; Lauzière, M; Rubin, P; Sirois, P | 1 |
| O'Donnell, M; Payne, AN | 1 |
| Knapp, HR | 1 |
| Bendele, AM; Fleisch, JH; Wong, WS | 1 |
| Albert, D; Braeckman, R; Carter, G; Dubé, L; Hansen, R; Rubin, P; Swanson, L | 1 |
| Bell, RL; Brooks, DW; Carter, GW; Lanni, C; Summers, JB; Young, PR | 1 |
| Albert, DH; Bell, RL; Bouska, J; Brooks, DW; Carter, GW; Dyer, R; Summers, JB; Young, PR | 1 |
| Barnes, NC; Barnes, PJ; Hui, KP; Kesterson, J; Rubin, P; Taylor, GW; Taylor, IK | 1 |
| Bukantz, SC | 1 |
| Bukhave, K; Lauritsen, K; Laursen, LS; Naesdal, J; Rask-Madsen, J | 1 |
| Anderson, CB; Mangino, MJ | 1 |
| Raub, W | 1 |
| Dermarkarian, R; Drazen, JM; Israel, E; Rosenberg, M; Rubin, P; Sperling, R; Taylor, G | 1 |
| Bruin, KF; Hommes, DW; Jansen, J; Tytgat, GN; van Deventer, SJ; Wouter ten Cate, J | 1 |
| Buckner, CK; Cook, E; Doran, O; Graziano, FM; Stahl, J | 1 |
| Awni, WM; Cohn, J; Drazen, JM; Fischer, AR; Frantz, R; Israel, E; McFadden, CA | 1 |
| Awni, WM; Brandwein, SR; Dube, LM; Granneman, GR; Locke, CS | 1 |
| Ado, VA; Mokronosova, MA; Perlamutrov, IuN | 1 |
| Bailie, MB; Carter, GW; Dahm, LJ; Harris, RR; Peters-Golden, M; Roth, RA | 1 |
| Bochnowicz, S; Underwood, DC | 1 |
| Chan, TC; Knapp, DW; Kuczek, T; Park, B; Reagan, WJ | 1 |
| Cohn, J; Kaminsky, DA; Martin, RJ; Trudeau, JB; Wenzel, SE; Westcott, JY | 1 |
| Buckner, CK; Conklin, R; Doran, O; Fishleder, RI; Graziano, FM; Will, JA | 1 |
| Cozzi, P; Leff, AR; Mitchell, RW; Ndukwu, IM; Padrid, PA; Shiou P [corrected to Shiue, P]; Shiue, P; Spaethe, S | 1 |
| Awni, WM; Braeckman, RA; Cavanaugh, JH; Granneman, GR; Locke, CS; St Peter, JV | 1 |
| Henson, PM; Hill, E; MacMillan, D; Murphy, RC; Sala, A | 1 |
| Ford-Hutchinson, AW | 1 |
| Chabot-Fletcher, M; Chilton, FH; Fonteh, AN; Huang, L; Marshall, LA; Sung, CM; Winkler, JD | 1 |
| Kazmi, SM; Lau, CY; Plante, RK; Taylor, GR; Visconti, V; Zhou, L | 1 |
| Brandwein, SR; Hackshaw, KV; Jones, K; Shi, Y; Westcott, JY | 1 |
| Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Igarashi, Y; Kaliner, MA; Lilly, CM; Rosenberg, MA; Rubin, P; White, MV | 1 |
| Bell, RL; Bouska, JB; Brooks, DW; Carter, GW; Harris, RR; Lanni, C; Malo, PE; Otis, ER; Stewart, AO | 1 |
| Camerini, R; Caputi, AP; Graziani, P; Squadrito, F; Zingarelli, B | 1 |
| Carpenter, TG; Cuthbert, NJ; Fitzgerald, MF; Francis, HP; Gardiner, PJ; Mohrs, K; Müller-Peddinghaus, R; Newton, BB; Patel, UP; Thompson, AM | 1 |
| Henson, PM; Hill, E; MacMillan, DK; Murphy, RC; Sala, A; Shuman, T; Sigal, E | 1 |
| Guidot, DM; Repine, JE; Repine, MJ; Westcott, JY | 1 |
| Bell, RL; Brooks, DW; Carter, GW; Malo, PE; Shaughnessy, TK; Summers, JB | 1 |
| Bell, RL; Brooks, DW; Carter, GW; Hansen, R; Lanni, C; Malo, PE; Rubin, P; Stewart, AO | 1 |
| Ellis, JL; Undem, BJ | 1 |
| Breton, J; Chabot-Fletcher, M; DeWolf, W; Griswold, D; Hillegass, L; Keller, P | 1 |
| Black, C; Brideau, C; Chan, C; Ford-Hutchinson, A; Frenette, R; Tagari, P | 1 |
| Anderson, CB; Mangino, MJ; Murphy, MK | 1 |
| Bell, RL; Bouska, J; Brooks, DW; Carter, GW; Lanni, C; Machinist, J; Malo, PE; Summers, JB; Young, PR | 1 |
| Busse, W; Cohn, J; Drazen, JM; Fish, J; Grossman, J; Israel, E; Kaiser, HB; Karahalios, P; Kemp, JP; Lanni, C; Ledford, D; Murray, JJ; Pearlman, H; Pierson, W; Rosenthal, R; Rubin, P; Segal, AT; Siegel, SC; Tinkelman, D; Wenzel, S | 1 |
| Callery, JC; Cohn, J; Drazen, JM; Fischer, AR; Israel, E; Lilly, CM; Rosenberg, MA; Rubin, P; Shapiro, J | 1 |
| Frossard, N; LeGall, G; Poaty, V; Riquet, M | 1 |
| Chertock, H; DiPasquale, G; Koeler, J; Peppard, J; Raychaudhuri, A; White, WD | 1 |
| Belfast, MT; Carlson, RP; Glaser, KB; Hartman, DA; Ochalski, SJ; Walter, TL | 1 |
| Fitzpatrick, FA; Lepley, RA | 1 |
| Howell, RE; Jenkins, LP; Rubin, EB; Sickels, BD; Weichman, BM; Woeppel, SL | 1 |
| Colombo, C; DiPasquale, G; Fryer, LR; Greenspan, PD; Haston, W; Healy, C; Kotyuk, B; Pastor, G; Pellas, TC; Raychaudhuri, A | 1 |
| Berkenkopf, JW; Carlson, RP; Grimes, D; Kreft, AF; Marinari, LR; Musser, JH; Sturm, RJ; Weichman, BM | 1 |
| Currie, JL; Isakson, PC; Rao, TS; Shaffer, AF | 1 |
| Kasiske, BL; Keane, WF; Kim, Y; O'Donnell, MP | 1 |
| Falgueyret, JP; Hutchinson, JH; Riendeau, D | 1 |
| Berkenkopf, JW; Grimes, D; Heaslip, RJ; Ilsemann, BA; Sickels, BD; Weichman, BM | 1 |
| Currie, JL; Isakson, PC; Kim, S; Rao, T; Shaffer, AF; Smith, WG; Thompson, JM | 1 |
| Blancuzzi, V; Chertock, H; Kimble, E; Koehler, J; Kowalski, T; Lee, W; Peters, P; Raychaudhuri, A; van Duzer, J | 1 |
| Carlson, RP; Gray, WB; Grimes, D; Hartman, DA; Howell, RE; Jenkins, LP; Kreft, AF; Kubrak, D | 1 |
| Chourmouzis, E; Fung-Leung, WP; Lau, CY; Pope, BL; Zhou, L | 1 |
| Carlson, RP; Glaser, K; Grimes, D; Gunawan, I; Hartman, DA; Howell, R; Kanzelberger, M; Malamas, MS; Nelson, JA; Shah, U | 1 |
| Clausen, M; Gautschi, K; Reinboth, JJ; Remé, CE | 1 |
| Cohn, J; Dworski, R; Fish, JE; Kane, GC; Kim, CJ; Murray, JJ; Peters, SP; Pollice, M; Sheller, J; Tollino, M | 1 |
| Cohn, J; Drazen, JM; Dubé, L; Israel, E | 1 |
| Medvedeff, ED; Nickerson-Nutter, CL | 1 |
| Bailie, MB; Fink, GD; Pearson, JM; Roth, RA | 2 |
| Braeckman, RA; Erdman, KA; Granneman, GR | 1 |
| Awni, WM; Cavanaugh, JH; Dubé, LM; Granneman, GR; Tzeng, TB; Witt, G | 1 |
| Awni, WM; Braeckman, RA; Cavanaugh, JH; Dubé, LM; Granneman, GR; Linnen, PJ; Locke, CS | 1 |
| Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Witt, G | 1 |
| Bopp, BA; Kukulka, MJ; Machinist, JM | 1 |
| Awni, WM; Braeckman, RA; Cavannaugh, JH; Granneman, GR; Locke, CS; Machinist, JM | 1 |
| Awni, WM; Braeckman, RA; Cavanaugh, JH; Chu, SY; Granneman, GR; Machinist, JM; Patterson, KJ | 1 |
| Awni, WM; Cavanaugh, JH; Dubé, LM; Granneman, GR; Witt, G | 1 |
| Awni, WM; Cavanaugh, JH; Dubé, LM; Granneman, GR; Hussein, Z; Patterson, KJ | 1 |
| Awni, WM; Braeckman, RA; Cavanaugh, JH; Dubé, LM; Granneman, GR; Locke, CS | 1 |
| Cavanaugh, JH; Granneman, GR; Mukherjee, D; Samara, E | 1 |
| Awni, WM; Cavanaugh, JH; Dubé, LM; el-Shourbagy, T; Locke, CS; Wong, SL | 1 |
| Awni, WM; Cavanaugh, JH; Dubé, LM; Granneman, GR; Hussein, Z | 1 |
| Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Locke, CS | 1 |
| Cohn, J; Dworski, RT; Fish, JE; Kane, GC; Kim, CJ; Murray, JJ; Peters, SP; Pollice, M; Sheller, JR | 1 |
| Bleecker, ER; Cohn, J; Hasday, JD; Meltzer, SS | 1 |
| Ferrero, JL; Machinist, JM; Mayer, MD; Rodrigues, AD; Shet, MS | 1 |
| Machinist, JM; Rodrigues, AD | 1 |
| Rainsford, KD; Smith, F; Ying, C | 1 |
| Elrod, L; Gay, CM; Morley, JA; Shada, DM; Wong, CF | 1 |
| Busse, WW; McGill, KA | 1 |
| Harada, K; Hibi, S; Kawahara, T; Kobayashi, N; Miyamoto, K; Numata, H; Okamoto, Y; Shinoda, M; Tagami, K; Yamatsu, I | 1 |
| Hussey, HJ; Tisdale, MJ | 1 |
| Broutman, L; Callaghan, C; Doria, MI; Eiznhamer, D; Keshavarzian, A; Zarif, A | 1 |
| Andresen, CJ; Eggler, JF; Smith, WB; Turner, CR; Watson, JW | 1 |
| Ganey, PE; Peters-Golden, M; Schiamberg, E; Tithof, PK | 1 |
| Smith, LJ | 1 |
| Dubé, LM; Lancaster, J; Liu, MC | 1 |
| Tanaka, R | 1 |
| Jackson, SK; Larsen, JS | 1 |
| Bell, RL; Carter, GW; Goodfellow, C; Harris, RR; Namovic, MT; Walsh, RE | 1 |
| Bartolí, R; Bertrán, X; Castellá, E; Esteve, M; Fernández-Bañares, F; Gassull, MA; Mañé, J; Ojanguren, I | 1 |
| Bolognese, B; Marshall, LA; Roshak, A; Winkler, JD | 1 |
| Dube, LM; Hawkey, CJ; Lancaster, JF; Linnen, PJ; Rountree, LV | 1 |
| Douglas, I; Herrnreiter, A; Leff, AR; Mayer, D; Muñoz, NM; Zhu, X | 1 |
| Awni, WM; Cao, G; Cavanaugh, JH; Dube, LM; Kasier, J; Leese, P; Locke, CS | 1 |
| Kotadia, B; Mangino, JE; Mangino, MJ; Sielczak, M | 1 |
| Awni, WM; Cavanaugh, JH; Dube, LM; Locke, C | 1 |
| Awni, WM; Chu, SY; Drajesk, J; Halstenson, CE; Hansen, R; Keane, WF; Machinist, JM; Patterson, K; Wong, S | 1 |
| Lau, R | 1 |
| Schiff, M | 1 |
| Spector, SL; Tan, RA | 1 |
| Magnussen, H; Rabe, KF; Watson, N | 2 |
| Bell, RL; Bouska, JJ; Brooks, CD; Carter, GW; Goodfellow, CL; Stewart, AO | 1 |
| Bell, RL; Harris, RR; Komater, VA; Marett, RA; Wilcox, DM | 1 |
| Brock, TG; McNish, RW; Peters-Golden, M | 1 |
| Dubé, LM; Lancaster, JF; Petty, T; Schwartz, HJ; Swanson, LJ | 1 |
| Drazen, JM | 1 |
| Bootsma, GP; Dekhuijzen, PN; Festen, J; van den Berg, LR; van Herwaarden, CL; Wielders, PL | 1 |
| Tan, RA | 1 |
| Kearney, AS; McLoughlin, M; Palepu, NR | 1 |
| Wenzel, SE | 1 |
| Cheskin, H; Hui, HW; Qiu, Y | 1 |
| Bochenek, G; Boodhoo, TI; Dahlén, B; Dahlén, SE; Dubé, LM; Kumlin, M; Mastalerz, L; Nizankowska, E; Pinis, G; Swanson, LJ; Szczeklik, A; Wright, S; Zetterström, O | 1 |
| Spector, S; Tan, RA | 1 |
| Bolognese, B; Hubbard, WC; Jackson, JR; Mangar, CA; Marshall, LA; Winkler, JD | 1 |
| Busse, WW; Horwitz, RJ; McGill, KA | 1 |
| Barberà, JA; Chung, KF; Gómez, FP; Iglesia, R; Roca, J; Rodriguez-Roisin, R | 1 |
| Aoki, Y; Kao, PN; Qiu, D; Zhao, GH | 1 |
| Drazen, J | 1 |
| Callens, E; Djebbar, R; Ruff, F; Santais, MC | 1 |
| Bouboulis, D; Frieri, M; Lark, G; Sansone, G; Schaefer, PA; Therattil, JM; Wang, SF; Zitt, M | 1 |
| Ellis, MH | 1 |
| Abraham, WM; Ahmed, A; Botvinnikova, Y; Lauredo, IT; Sabater, JR | 1 |
| Lane, SJ | 1 |
| Andry, C; Dolan, R; Grillone, G; Hartshorn, K; McAvoy, D; Suntra, C; Tablante, J | 1 |
| Abraham, WM; Allegra, L; Scuri, M | 1 |
| Dubé, LM; DuBuske, LM; Grossman, J; Lancaster, JF; Swanson, LJ | 1 |
| Carpentier, PJ; Dubé, LM; Kemp, JP; Lancaster, JF; Lazarus, SC; Lee, T; Ochs, RF; Wenzel, S | 1 |
| Carlson, R; Glaser, K; Hartman, D; Kreft, A; Lock, Y; Tomchek, L; Weichman, B | 1 |
| Dahlén, SE; Larsson, L; Sydbom, A | 1 |
| Hardy, DB; Pereria, LE; Yang, K | 1 |
| Wedekind, CA | 1 |
| Colombel, JF; Desreumaux, P; Ectors, N; Geboes, K; Jouret, A; Rutgeerts, P | 1 |
| Kuna, P; Kupczyk, M | 1 |
| Simon, RA; Woodmansee, DP | 1 |
| Hirasawa, N; Kushihara, M; Ohuchi, K; Takahagi, H; Takasaki, W; Takayanagi, M; Yamashita, M | 1 |
| Bleecker, ER; Dubé, LM; Hasday, JD; Hebel, JR; Lanni, C; Meltzer, SS; Moore, WC; Wisniewski, P | 1 |
| Heerschap, A; Mayatepek, E; Rotteveel, JJ; Steijlen, PM; Willemsen, MA | 1 |
| Dellaripa, PF; Drazen, J; Roth, ME; Wechsler, ME | 1 |
| Lang, DM | 1 |
| Daffern, PJ; Pauls, JD; Simon, RA; Stevenson, DD | 1 |
| Agustí, C; Cardell, LO; Nadel, JA | 1 |
| Mancuso, P; Peters-Golden, M | 1 |
| Bisgaard, H | 1 |
| Audouin, C; Hénichart, JP; Houssin, R; Lassoie, MA; Mestdagh, N | 1 |
| Drazen, JM; Dubé, L; Israel, E; Juniper, EF; Moy, ML; Weiss, ST | 1 |
| Bizer, C; Schapowal, A; Simon, HU; Thomet, OA; Wiesmann, UN | 1 |
| Krawiec, ME; Wenzel, SE | 1 |
| García-Marcos, L; Schuster, A | 1 |
| Spector, SL | 1 |
| Harada, K; Inoue, T; Nagakura, N; Oketani, K | 1 |
| Alcaraz, MJ; Guillén, MI; Vicente, AM | 1 |
| Crow, DW; Marsella, R; Nicklin, CF | 1 |
| Amacher, DE; Beierschmitt, WP; Griffiths, RJ; McNeish, JD; Nagahisa, A; Nakane, M | 1 |
| Taşkapan, MO | 1 |
| Coffey, MJ; Peters-Golden, M; Phare, SM | 2 |
| Adachi, M; Minoguchi, K | 1 |
| Chen, N; Reiss, CS; Restivo, A | 1 |
| Hayden, ML | 1 |
| Cruysberg, JR; Lutt, MA; Mayatepek, E; Nijhuis-van der Sanden, MW; Pasman, JW; Rotteveel, JJ; Steijlen, PM; van der Graaf, M; Willemsen, MA | 1 |
| Askonas, LJ; Ghoreishi-Haack, N; Kachur, JF; Liang, CD; Russell, MA; Smith, WG; Villani-Price, D; Won-Kim, S | 1 |
| Norwood, C; Skelton, H; Smith, KJ | 1 |
| Abbasi, AA; Dempsey, JA; Haverkamp, HC; Meyer, KC; Rice, AJ; Sonetti, DA; Wetter, TJ; Xiang, Z | 1 |
| Mastalerz, L; Nizankowska-Mogilnicka, E; Swierczyńska, M | 1 |
| Achucarro, P; Guski, H; Heinicken, D; Jacobi, CA; Kilian, M; Müller, JM; Schimke, I; Wenger, FA | 1 |
| Gunning, WT; Kramer, PM; Pereira, MA; Steele, VE | 1 |
| Bisevac, M; Guski, H; Khodadayan, C; Kilian, M; Müller, JM; Schimke, I; von Seebach, M; Wenger, FA | 1 |
| Capella, GL | 1 |
| Valacer, DJ | 1 |
| Badr, KF; Montero, A; Munger, KA; Valdivielso, JM | 1 |
| Chacur, M; Cury, Y; Guerra, JL; Gutiérrez, JM; Lomonte, B; Longo, I; Picolo, G; Teixeira, CF | 1 |
| Glori, M; Hintz, KH; Welliver, RC | 1 |
| Adler, YD; Camera, E; Cunliffe, WJ; Nestoris, S; Orfanos, CE; Orth, M; Picardo, M; Zouboulis, CC | 1 |
| Kast, RE | 1 |
| Dev, A; Leong, AB; Wu, X | 1 |
| Jung, A | 1 |
| Lu, P; Raab, CE; Rodrigues, AD; Schrag, ML; Shou, M; Slaughter, DE | 1 |
| Darling, T; Guardiano, RA; Lee, W; Norwood, C | 1 |
| Kemp, JP | 1 |
| Baliga, BS; Haynes, J; Obiako, B; Ofori-Acquah, S; Pace, B | 1 |
| Chordia, MD; Heasley, BH; Joshi, EM; Macdonald, TL | 1 |
| Blanc, PD; Eisner, MD; Katz, PP; Snyder, L; Yelin, EH | 1 |
| Gershwin, ME; Morrissey, BM; Naguwa, S; Vang, K; Watnik, M; Wineinger, J; Ziboh, VA | 1 |
| Kulkarni, SK; Patil, CS; Singh, VP | 2 |
| Britti, D; Chatterjee, PK; Cuzzocrea, S; Di Paola, R; Patel, NS; Sautebin, L; Thiemermann, C | 1 |
| Fiorucci, S; Hollenberg, MD; von der Weid, PY; Wallace, JL | 1 |
| Collin, M; Collino, M; Cuzzocrea, S; Di Paola, R; Hadley, J; Patel, NS; Rossi, A; Sautebin, L; Thiemermann, C | 1 |
| Erlendsdóttir, H; Gunnarsson, E; Haraldsson, A; Olafsson, O; Thors, VS | 1 |
| Beer, DG; Chen, X; Giordano, TJ; Jin, Z; Lin, Y; Lubet, RA; Shih, WC; Sood, S; Wang, P; Wang, S; Wu, N; Yang, CS | 1 |
| Leru, P | 1 |
| Boschnakow, A; Saborowski, A; Zouboulis, ChC | 1 |
| Elstad, MR; Grissom, CK; Richer, LD | 1 |
| Chen, X; Fang, M; Li, N; Sood, S; Sun, Z; Wang, P; Wang, S; Yang, CS | 1 |
| Baliga, BS; Gardner, R; Haynes, J; Kuvibidila, S; Ode, D; Velez, M; Warrier, R; Yu, L | 1 |
| Dahlén, SE; Kumlin, M; Larsson, BM; Larsson, K; Palmberg, L; Sundblad, BM | 1 |
| Gregor, JI; Heukamp, I; Jacobi, CA; Kiewert, C; Kilian, M; Kristiansen, G; Schimke, I; Walz, MK; Wenger, FA | 1 |
| Hénichart, JP; Pommery, J; Pommery, N | 1 |
| Kulkarni, SK; Kumar, M; Patil, CS; Singh, VP | 1 |
| Dahlén, SE | 1 |
| Aronoff, DM; Canetti, C; Chen, GH; Choe, M; Flamand, N; Peters-Golden, M; Toews, GB; Wettlaufer, S | 1 |
| Haynes, J; Hester, RB; King, JA; Obiako, B; Ofori-Acquah, S | 1 |
| Mazziotti, DA; Rohrman, BA | 1 |
| Capra, V; Cole, DE; Folco, G; Rovati, GE; Sala, A; Thompson, MD | 1 |
| Angersbach, BS; Karlage, K; Kuehl, PJ; Merrill, BA; Myrdal, PB; Wightman, PD | 1 |
| Ludington, E; Mehra, P; Simon, RA; Stevenson, DD; White, A | 1 |
| Chandrasekaran, A; Jordan, R; Li, H; Markiewicz, V; Scatina, J; Shen, L; Tong, Z; Xiang, Q | 1 |
| Dickerson, KS; Luttermoser, GK; Scow, DT | 1 |
| Dahlén, B; Dahlén, SE; Delin, I; Gaber, F; James, A; Kumlin, M; Sampson, AP; Wetterholm, A | 1 |
| Balter, M; Boulet, LP; Cairns, CB; Löfdahl, CG; O'Connor, BJ; Szczeklik, A | 1 |
| Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Jiang, X; Karlsson, L; Lundeen, KA; Rao, NL; Riley, JP; Williams, KN; Xue, X | 1 |
| Berger, W; Cairns, CB; De Chandt, MT | 1 |
| Busse, W; Calhoun, W; Dube, L; Harris, J; Panettieri, R; Peters-Golden, M; Russell, H; Walton-Bowen, K; Wenzel, S | 1 |
| Funk, AJ; Kosanke, SD; Li, CS; Lokey, SJ; Mandrell, TD; Potters, CF | 1 |
| Berger, W; Casale, T; Corren, J; Dube, L; Kemp, J; LaVallee, N; Nelson, H; Stepanians, M; Walton-Bowen, K | 1 |
| Cameron, CM; Dube, LM; Kasten, LE; Walton-Bowen, K; Watkins, PB | 1 |
| Andoh, T; Kamimura, K; Kawai, S; Kuraishi, Y; Nakano, T; Nojima, H; Ohtsuka, E | 1 |
| Chordia, MD; Li, F; Macdonald, TL; Woodling, KA | 1 |
| Bramanti, P; Caminiti, R; Cuzzocrea, S; Di Paola, R; Genovese, T; Mazzon, E; Muià, C; Rossi, A; Sautebin, L | 1 |
| Denis, JN; Guinchard, X | 1 |
| Amann, JM; Backlund, MG; Johnson, DH | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Anderson, GD; Dufield, DR; Hardy, MM; Masferrer, JL; Pufahl, RA; Zweifel, BS | 1 |
| Butler, BD; Little, T | 1 |
| Alves, AS; Britto, LR; Curi, R; Cury, Y; Della-Casa, MS; Gonçalves, LR; Greco, K; Otton, R; Sampaio, SC; Spadacci-Morena, DD; Sudo-Hayashi, LS; Zambelli, VO; Zychar, BC | 1 |
| Donoghue, DJ; McAndrew, CW; Meyer, AN | 1 |
| Borey, AJ; Clark, JD; Cui, J; Donahue, F; Han, L; Hassan-Zahraee, M; Leach, MW; Lee, KL; Marusic, S; McKew, JC; Pelker, JW; Shen, MW; Shimizu, T; Stedman, NL; Thakker, P; Wolf, SF; Xu, X | 1 |
| Chen, Z; Fang, SH; Huang, XJ; Li, CT; Lu, YB; Qi, LL; Wei, EQ; Yuan, YM; Zhang, L; Zhang, LH; Zhang, WP | 1 |
| Bhattacharjee, R; Dayyat, E; Goldman, JL; Gozal, D; Kheirandish-Gozal, L; Serpero, LD; Snow, A | 1 |
| Klanderman, B; Lima, J; Sylvia, J; Tantisira, KG; Weiss, ST | 1 |
| Fegn, L; Wang, Z | 1 |
| Heasley, BH; Joshi, EM; Macdonald, TL | 1 |
| Chen, CM; Shi, SS; Tu, XK; Wang, CH; Yang, WZ | 1 |
| Arias, K; Baig, M; Chu, D; Colangelo, M; Coyle, A; Goncharova, S; Jordana, M; Vadas, P; Walker, T; Waserman, S | 1 |
| Gelb, AF; Shinar, C; Simmons, M; Taylor, CF | 1 |
| Ayers, DC; Fanning, PJ; Gaur, T; Lian, JB; Mason-Savas, A; O'Connell, SL; Silva, J; Stein, GS; Wixted, JJ | 1 |
| Anderson, GD; Cortes-Burgos, LA; Graneto, MJ; Happa, FA; Hardy, MM; Hu, G; Masferrer, JL; Muthian, S; Pufahl, RA; Settle, SL; Stewart, Z; Weir, DE; Zweifel, BS | 1 |
| Alestas, T; Seltmann, H; Zouboulis, CC | 1 |
| Li, W; Lou, TF; Mackie, A; Pace, BS; Singh, M | 1 |
| Hu, JH; Li, FQ; Liu, JY; Liu, YX; Pan, YH; Peng, C; Wang, XR; Wu, L; Xu, JG; You, BM; Zhu, QG; Zhu, Y | 1 |
| Choi, HE; Kwak, HJ; Lim, HJ; Park, HY; Park, JH; Park, KM | 1 |
| Chen, Y; Li, D; Li, S | 1 |
| Bates, G; Di Capite, J; Nelson, C; Parekh, AB | 1 |
| Horn, TL; Johnson, WD; Lubet, RA; McCormick, DL; Phillips, JM; Steele, VE | 1 |
| Jensen, A; Karlage, KL; Mogalian, E; Myrdal, PB | 1 |
| Chen, CM; Jin, CD; Shi, SS; Tu, XK; Wang, CH; Wen, S; Yang, WZ; Yang, YK; Zhang, YL | 1 |
| DeMarcantonio, MA; Han, JK | 1 |
| Boschi, D; Cena, C; Coruzzi, G; Di Stilo, A; Fruttero, R; Gasco, A; Giorgis, M; Guaita, E; Morini, G; Talniya, NC | 1 |
| Bramanti, P; Cuzzocrea, S; Dehm, F; Hoffmann, M; Koeberle, A; Pergola, C; Rossi, A; Sautebin, L; Werz, O | 1 |
| Dropinski, J; Rzeszutko, M; Sanak, M; Sokołowska, B; Szczeklik, A; Szczeklik, W | 1 |
| Albert, RK; Bailey, WC; Casaburi, R; Connett, JE; Cooper, JA; Criner, GJ; Curtis, JL; Dransfield, MT; Han, MK; Harnden, SM; Kim, V; Lazarus, SC; Marchetti, N; Martinez, FJ; McEvoy, CE; Niewoehner, DE; Reilly, JJ; Rice, K; Scanlon, PD; Scharf, SM; Sciurba, FC; Washko, GR; Woodruff, PG | 1 |
| Chu, J; Praticò, D | 2 |
| Chen, WJ; Li, CT; Wei, EQ; Zhang, LH; Zhang, XY; Zhao, JB | 1 |
| Gibbons, RD; Joo, MJ; Lee, TA; Schumock, GT; Stayner, LT; Valuck, RJ | 1 |
| Kroegel, C | 1 |
| Andoh, T; Honma, A; Kitazawa, K; Kuraishi, Y; Sakai, K; Urashima, M | 1 |
| Amghar, H; Bouloumié, A; Bourlier, V; Féral, CC; Filloux, C; Galitzky, J; Grimaldi, PA; Mothe-Satney, I; Neels, JG; Pons, C; Van Obberghen, E | 1 |
| Fang, SH; Huang, XQ; Lin, KN; Lu, YB; Wei, EQ; Zhang, WP | 1 |
| Acikgoz, S; Baba, F; Banoglu, ZN; Dengiz, GO; Isikdemir, F; Kelek, S; Kurcer, Z; Sipahi, EY | 1 |
| da Silva, NG; Gonçalves, LR; Sampaio, SC | 1 |
| Chu, J; Giannopoulos, PF; Joshi, YB; Kirby, LG; Li, JG; Praticò, D; Sperow, M | 1 |
| Chen, W; Han, H; Li, C; Wei, E; Zhang, L; Zhang, X; Zhao, J | 1 |
| Atemnkeng, VA; Dong, LL; Kaiser, A; Langer, B; Laufer, S; May, C; Pink, M; Schmitz-Spanke, S; Wu, XJ; Zhao, KH | 1 |
| Cuperlovic-Culf, M; Ferguson, D; Hébert, MJ; Jean-François, J; LeBlanc, LM; Morin, P; Paré, AF; Surette, ME; Touaibia, M | 1 |
| Akpa, EG; Bosworth, BP; Boyle, JO; Brown, PH; Dannenberg, AJ; Duffield-Lillico, AJ; Kingsley, PJ; Knutson, A; Marnett, LJ; Milne, GL; Mohebati, A; Szabo, E; Zhou, XK | 1 |
| Chen, CM; Chen, Y; Shi, SS; Tu, XK; Wang, CH; Yang, WZ | 1 |
| Chu, J; Li, JG; Praticò, D | 1 |
| Seow, CY; van Eeden, S | 1 |
| Chang, FT; Chen, WJ; Liaw, SF; Lin, CC; Lin, MW | 1 |
| Christians, U; Clavijo, CF; Galinkin, JL; Hoffman, K; Labovitz, E; Malik, P; Pian, P; Rzasa Lynn, R; Vinks, AA | 1 |
| Cao, R; Liu, T; Meng, Z; Wang, X; Wang, Y; Yang, Z | 1 |
| Fan, B; Gao, W; Li, B; Li, M; Liu, H; Qu, X; Shao, Q; Wang, Q; Wen, Z; Xie, Q; Yang, Y; Yu, J; Zhao, F | 1 |
| Adesina, SE; Hart, CM; Kang, BY; Murphy, TC; Porter, KM; Sutliff, RL | 1 |
| Andoh, T; Kuraishi, Y; Takayama, Y | 1 |
| Di Meco, A; Lauretti, E; Praticò, D; Vagnozzi, AN | 1 |
| Chen, L; Li, CT; Wang, XR; Wang, YF; Wei, EQ; Xu, DM; Zhang, LH; Zhang, XY | 1 |
| Bujalska-Zadrozny, M; Gasinska, E; Maslinski, S; Rzodkiewicz, P | 1 |
| Cao, W; Ding, XL; Qu, LS; Wu, SB; Zhang, H; Zhang, HF; Zhou, GX | 1 |
| Bentrem, DJ; Blatner, NR; Cheon, EC; Gounaris, E; Grippo, PJ; Heiferman, JR; Heiferman, MJ; Khazaie, K; Knab, LM; Munshi, HG; Phillips, JD; Shrivastav, M; Vitello, D | 1 |
| Abood, M; Chu, J; Giannopoulos, PF; Kirby, LG; Li, JG; Praticò, D; Sperow, M; Yu, WH | 1 |
| Dahlin, A; Irvin, CG; Kubo, M; Lima, JJ; Litonjua, A; Peters, SP; Tamari, M; Tantisira, KG | 1 |
| Bastiaans, DE; Fuijkschot, J; Roeleveld, N; Seyger, MM; Wevers, RA; Willemsen, MA | 1 |
| Cheng, J; Jia, J; Li, Y; Liu, Y; Wang, W; Xiao, Y | 1 |
| Barcelos, Lda S; de Miranda, AS; de Oliveira, AC; Machado, FS; Moraes, MF; Parreiras, PM; Rachid, MA; Resende, GH; Rodrigues, FG; Silva, BC; Silveira, AL; Teixeira, AL; Teixeira, MM | 1 |
| Pasichnichenko, OM; Vinogradova, OO; Yanchuk, PI | 1 |
| Arumugam, PI; Brandt, EB; Carmeliet, P; Eiymo Mwa Mpollo, MS; Hershey, GK; Jonck, B; Kalra, VK; Le Cras, TD; Lindsey, M; Loberg, A; Malik, P; Pillis, D; Ratner, N; Rizvi, T; Shanmukhappa, SK; Tiwari, S; Wills-Karp, M | 1 |
| Dennis, EA; Mouchlis, VD | 1 |
| Bretzke, S; Essig, S; Koeberle, A; Menche, D; Müller, R; Scherer, O; Schmalzbauer, B; Werz, O | 1 |
| Chen, CM; Liang, RS; Shi, SS; Tu, XK; Wang, CH; Yang, WZ; Zhang, HB | 1 |
| Hah, JH; Jeong, WJ; Oh, SM; Park, SW; Sung, MW | 1 |
| Altavilla, D; Arcoraci, V; Bitto, A; Galfo, F; Irrera, N; Macrì, A; Minutoli, L; Pallio, G; Pizzino, G; Squadrito, F; Squadrito, G | 1 |
| Antonov, VG; Krutetskaya, ZI; Milenina, LS; Naumova, AA; Nozdrachev, AD | 1 |
| Chen, Y; DeSouza, N; Guo, Z; Hoffman, R; Li, S; Liang, A; Lu, M; Shan, Y | 1 |
| Abueid, L; Alican, İ; Cumbul, A; Ercan, F; Uslu, Ü; Velioğlu Öğünç, A | 1 |
| Gaboriaud-Kolar, N; Garscha, U; Halabalaki, M; Kouloura, E; Krauth, V; Pace, S; Pergola, C; Rossi, A; Sautebin, L; Skaltsounis, AL; Svouraki, A; Werz, O | 1 |
| Barrero, C; Li, JG; Merali, S; Praticò, D | 1 |
| Afenjar, A; Boespflug-Tanguy, O; Pichard, S; Sarret, C | 1 |
| Gleitz, S; Hoffmann, DB; Komrakova, M; Kosinsky, RL; Menger, B; Nguyen, HH; Saul, D; Sehmisch, S; Wassmann, M | 1 |
| Corrêa, JD; Cunha, TM; Garlet, GP; Machado, FS; Madeira, MFM; Queiroz-Junior, CM; Silva, TA; Souza, DG; Teixeira, MM; Werneck, SMC | 1 |
| Blanchard, S; Boudreau, LH; Cormier, M; Doucet, MS; Lassalle-Claux, G; Surette, ME; Touaibia, M | 1 |
| Cheon, HG; Choi, HE; Kwak, HJ | 1 |
| Akyol, O; Huang, L; McBride, DW; Sherchan, P; Wang, Y; Zhang, JH | 1 |
| Domon, H; Isono, T; Kawabata, S; Kurosawa, M; Maekawa, T; Oda, M; Terao, Y; Yamaguchi, M | 1 |
| Dehm, F; Gerstmeier, J; Koeberle, A; Laufer, S; Maier, TJ; Northoff, H; Pace, S; Pein, H; Pergola, C; Rådmark, O; Rossi, A; Rummler, S; Samuelsson, B; Sautebin, L; Schaible, AM; Troisi, F; Weinigel, C; Werz, O | 1 |
| Gasimov, T; Hoffmann, DB; Komrakova, M; Menger, B; Ninkovic, M; Rohde, V; Saul, D; Sehmisch, S; Simka, P; Wolff, L | 1 |
| Du, YF; Hong, H; Hu, M; Li, DD; Long, Y; Reed, MN; Suppiramaniam, V; Tang, SS; Xie, H | 1 |
| Mosser-Goldfarb, JL; Yanes, DA | 1 |
| Dahlin, A; Irvin, CG; Kubo, M; Lima, JJ; Litonjua, AA; Peters, SP; Qiu, W; Tamari, M; Tantisira, KG; Weiss, ST; Wu, AC | 1 |
| Hashim, AA; Helmy, MM; Mouneir, SM | 1 |
| Arentson, E; Belikoff, B; Brooks, FJ; Byers, DE; Castro, M; Chen, DL; Engle, JT; Fujiwara, H; Huang, HJ; Isakow, W; Kemp, D; Phillips, S; Pierce, RA; Scherrer, DE; Shifren, A; Spayd, KJ | 1 |
| Liao, D; Qian, B; Wu, K; Xu, M; Zhang, Y | 1 |
| Chiu, J; Giannopoulos, PF; Praticò, D | 2 |
| Ahmadieh, H; Hafezi-Moghadam, A; Ishibashi, T; Ishikawa, K; Kanavi, MR; Koga, T; Nakama, T; Nakao, S; Ohba, M; Okuno, T; Penninger, JM; Saeki, K; Sasaki, F; Sonoda, KH; Yokomizo, T; Yoshida, S | 1 |
| Borges, RDS; Brasil, DDSB; Campos, JM; Costa, JDS; Costa, KDSL; Ferreira, EFB; Macêdo, WJDC; Ramos, RDS; Santos, CBRD; Silva, CHTPD | 1 |
| Balamurali, MM; Basu, B; Doble, M; Munussami, P; Muthuraman, S; Saravana Kumar, R; Sinha, S; Vasavi, CS; Waidha, KM | 1 |
| Butterfield, J; Castells, M | 1 |
| Adams, KN; Ebert, CS; Farquhar, DR; Lee, SE; Masood, MM; Senior, BA; Thorp, BD; Zanation, AM | 1 |
| Kwak, HJ; Lee, SS; Lim, HJ; Park, J; Um, JY | 1 |
| Abasolo, I; Andrade, F; Arango, D; Díaz-Riascos, ZV; Gener, P; González, P; Manzano, A; Martínez-Trucharte, F; Montero, S; Rafael, D; Sayós, J; Schwartz, S; Seras-Franzoso, J; Xandri-Monje, H | 1 |
| Cai, Z; Chen, JJ; Deng, W; Duan, M; Guo, Y; Liu, C; Tang, Q; Wang, J; Wu, QQ; Xiao, Y; Xie, S; Yuan, Y | 1 |
| Bobade, PS; Dhumal, DM; Ganorkar, SB; Lokwani, DK; Shirkhedkar, AA; Vander Heyden, Y | 1 |
| Alvarez, ML; Carrillo, MC; Ceballos, MP; Comanzo, CG; Lorenzetti, F; Lucci, A; Monti, JA; Pisani, GB; Quiroga, AD; Ronco, MT; Tordjmann, T; Vera, MC | 1 |
| Holguin, F; Nouraie, M; Parikh, A; Thalanayar Muthukrishnan, P | 1 |
| Enache, I; Kubick, N; Manda, G; Mickael, ME; Pajares, M | 1 |
| Chen, X; Fan, W; Huang, C; Jacobson, O; Kang, F; Li, L; Ma, Y; Mu, Q; Tang, L; Wang, M; Wang, Z; Yang, W; Yu, Z; Zhou, Z | 1 |
| Huang, CW; Hung, TY; Wu, SN | 1 |
| Citron, F; Deem, AK; Genovese, G; Perelli, L; Viale, A | 1 |
| Chiasson, AI; Hébert, MPA; Mbarik, M; Ndongou Moutombi, FJ; Robichaud, S; Surette, ME; Touaibia, M | 1 |
| Chen, H; Deng, Y; Guo, Z; He, Z; Liang, Y; Liu, L; Sun, X; Zhang, P; Zhang, Z | 1 |
| Baek, SE; Choi, JM; Jang, EJ; Jeon, EY; Kim, CD; Kim, JO | 1 |
| Duan, P; Lin, J; Long, J; Tang, J; Zhang, C; Zhu, H | 1 |
| Cavallaro, G; Craparo, EF; Drago, SE; Luxenhofer, R | 1 |
| Franz, MK; Hohl, FE; Komrakova, M; Meyer, I; Roch, PJ; Saul, D; Sehmisch, S; Taudien, S | 1 |
| Li, L; Wang, S; Xiao, Y; Xu, Z | 1 |
| Chang-Chien, GP; Chen, A; Hsiao, YT; Ke, MC; Lee, JJ; Lin, S; Lin, TK | 1 |
| Lin, CL; Su, HY; Tsai, HP; Tsai, YC | 1 |
| Jang, H; Jang, WI; Jang, WS; Kim, H; Kwak, SY; Lee, SB; Lee, SJ; Na, J; Park, M; Park, S; Shim, S | 1 |
40 review(s) available for zileuton and hydroxyurea
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.
Topics: Animals; Arachidonate 5-Lipoxygenase; Drug Design; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors | 1992 |
[Allergy and leukotrienes].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Asthma; Dermatitis, Atopic; Humans; Hydroxyurea; Hypersensitivity; Leukotrienes; Lipoxygenase Inhibitors; Receptors, Leukotriene | 1995 |
Leukotriene antagonists and inhibitors: clinical applications.
Topics: Animals; Asthma; Glomerulonephritis; Humans; Hydroxyurea; Indoles; Inflammatory Bowel Diseases; Leukotriene Antagonists; Leukotrienes; Membrane Proteins; Propionates; Psoriasis; Quinolines; Receptors, Leukotriene | 1995 |
Inhibition of CoA-independent transacylase reduces inflammatory lipid mediators.
Topics: Acyltransferases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Humans; Hydroxyurea; Imidazoles; Inflammation; Mast Cells; Monocytes; Neutrophils; Organophosphorus Compounds | 1995 |
Zileuton.
Topics: Arthritis, Rheumatoid; Asthma; Humans; Hydroxyurea; Lipoxygenase Inhibitors | 1996 |
Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea; Indoles; Inflammation; Inflammation Mediators; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Phenylcarbamates; Sulfonamides; Tosyl Compounds | 1996 |
[5-lipoxygenase inhibitors in asthma therapy].
Topics: Arachidonate 5-Lipoxygenase; Arachidonic Acids; Asthma; Humans; Hydroxyurea; Lipoxygenase Inhibitors | 1996 |
Antileukotriene therapy for asthma.
Topics: Asthma; Humans; Hydroxyurea; Inflammation; Leukotrienes; Lipoxygenase Inhibitors | 1996 |
Emerging treatments for rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Antirheumatic Agents; Arthritis, Rheumatoid; CD4 Antigens; Collagen; Cyclosporine; Humans; Hydroxyurea; Immunosuppressive Agents; Interleukin-1; Minocycline; Mycophenolic Acid; Tumor Necrosis Factor-alpha | 1997 |
Antileukotriene agents.
Topics: Anti-Asthmatic Agents; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Phenylcarbamates; Sulfonamides; Tosyl Compounds | 1997 |
New directions in asthma drug therapy.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Chromones; Humans; Hydroxyurea; Indoles; Inflammation; Leukotrienes; Lipoxygenase Inhibitors; Phenylcarbamates; Sulfonamides; Tosyl Compounds | 1998 |
The role of antileukotrienes in asthma management.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Lipoxygenase Inhibitors; Phenylcarbamates; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds | 1998 |
New approaches to anti-inflammatory therapy for asthma.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Dicarboxylic Acids; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Phenylcarbamates; Steroids; Sulfonamides; Tosyl Compounds | 1998 |
The role of leukotriene modifiers in the treatment of asthma.
Topics: Animals; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Phenylcarbamates; Sulfonamides; Tosyl Compounds | 1998 |
Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Lipoxygenase Inhibitors; Phenylcarbamates; Randomized Controlled Trials as Topic; Sulfonamides; Tosyl Compounds; Treatment Outcome | 1998 |
[Potential importance of antileukotrienes in the treatment of asthma and other inflammatory diseases: apropos of a new pharmacological class].
Topics: Acetophenones; Adult; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Asthma; Bronchoconstriction; Child; Clinical Trials as Topic; Crohn Disease; Cystic Fibrosis; Haplorhini; Humans; Hydroxyurea; Indazoles; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Phenylcarbamates; Psoriasis; Randomized Controlled Trials as Topic; Respiratory Distress Syndrome; Sulfonamides; Tetrazoles; Tosyl Compounds | 1998 |
Leukotriene antagonism in asthma and rhinitis.
Topics: Acetates; Asthma; Bronchi; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotriene D4; Lipoxygenase Inhibitors; Membrane Proteins; Phenylcarbamates; Quinolines; Receptors, Leukotriene; Rhinitis; Sinusitis; Sulfides; Sulfonamides; Tosyl Compounds | 1998 |
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy; Colitis, Ulcerative; Colon; Crohn Disease; Cyclosporine; Humans; Hydroxyurea; Ileum; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mesalamine; Microscopy; Sulfasalazine; Time Factors | 1999 |
[The role of leukotrienes in inflammation and leukotriene inhibitors].
Topics: Acetates; Arachidonate 5-Lipoxygenase; Asthma; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Phenylcarbamates; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds | 1999 |
Leukotriene modifiers in pediatric asthma management.
Topics: Acetates; Adrenal Cortex Hormones; Anti-Asthmatic Agents; Asthma; Child; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Membrane Proteins; Phenylcarbamates; Quinolines; Receptors, Leukotriene; Sulfides; Sulfonamides; Tosyl Compounds | 2001 |
Leukotriene inhibitors and non-steroidal therapies in the treatment of asthma.
Topics: Acetates; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Asthma; Bronchoconstriction; Child; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Phenylcarbamates; Phosphodiesterase Inhibitors; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds; Treatment Outcome | 2001 |
Antileukotrienes in asthma: present situation.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Chromones; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Phenylcarbamates; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds | 2001 |
[Leukotriene modifiers].
Topics: Acetates; Asthma; Chromones; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Membrane Proteins; Phenylcarbamates; Practice Guidelines as Topic; Quinolines; Receptors, Leukotriene; Sulfides; Sulfonamides; Tosyl Compounds | 2001 |
Leukotriene modifiers. Expanded role may be on horizon.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Lipoxygenase Inhibitors; Patient Compliance; Phenylcarbamates; Quinolines; Safety; Steroids; Sulfides; Sulfonamides; Tosyl Compounds; Treatment Outcome | 2000 |
[Anti-leukotriene drugs and Churg Strauss syndrome].
Topics: Churg-Strauss Syndrome; Humans; Hydroxyurea; Leukotriene Antagonists | 2002 |
New treatments for asthma: the role of leukotriene modifier agents.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Asthma, Exercise-Induced; Cyclopropanes; Drug Evaluation; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Phenylcarbamates; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds; Treatment Outcome | 1999 |
[Anti-leukotrienes in allergic diseases in children].
Topics: Acetates; Asthma; Child; Cyclopropanes; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotrienes; Membrane Proteins; Quinolines; Receptors, Leukotriene; Sulfides | 2003 |
Recent advances in the management of asthma using leukotriene modifiers.
Topics: Acetates; Administration, Inhalation; Adolescent; Adult; Asthma; Child; Child, Preschool; Chromones; Controlled Clinical Trials as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukotriene Antagonists; Male; Middle Aged; Peak Expiratory Flow Rate; Quinolines; Respiratory Function Tests; Severity of Illness Index; Sulfides; Treatment Outcome | 2003 |
Leukotrienes antagonists in the management of bronchial asthma.
Topics: Asthma; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotrienes | 2003 |
Treatment of asthma with antileukotrienes: first line or last resort therapy?
Topics: Acetates; Animals; Asthma; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotriene C4; Leukotriene D4; Leukotriene E4; Lipoxygenase Inhibitors; Membrane Proteins; Quinolines; Receptors, Leukotriene; Respiratory System; Rhinitis; Sulfides | 2006 |
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends.
Topics: Adult; Animals; Asthma; Cardiovascular Diseases; Child; Child, Preschool; Dermatitis, Atopic; Female; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotriene C4; Leukotriene D4; Leukotriene E4; Membrane Proteins; Pharmacogenetics; Receptors, Leukotriene; Receptors, Purinergic; Recombinant Proteins; Rhinitis, Allergic, Seasonal; SRS-A; Tissue Distribution | 2007 |
Leukotriene inhibitors in the treatment of allergy and asthma.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Asthma, Exercise-Induced; Cyclopropanes; Dermatitis, Atopic; Humans; Hydroxyurea; Hypersensitivity; Indoles; Leukotriene Antagonists; Phenylcarbamates; Quinolines; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Sulfides; Sulfonamides; Tosyl Compounds | 2007 |
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Dermatitis, Atopic; Drug Administration Schedule; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Pulmonary Disease, Chronic Obstructive; Rhinitis | 2007 |
Systemic therapies in managing sinonasal inflammation.
Topics: Anti-Inflammatory Agents; Combined Modality Therapy; Drug Therapy; Eosinophils; Histamine Antagonists; Humans; Hydroxyurea; Immunologic Factors; Indoles; Leukotriene Antagonists; Otorhinolaryngologic Surgical Procedures; Phenylcarbamates; Rhinitis; Sinusitis; Sulfonamides; Tosyl Compounds | 2010 |
Association between leukotriene-modifying agents and suicide: what is the evidence?
Topics: Acetates; Adverse Drug Reaction Reporting Systems; Cyclopropanes; Drug Labeling; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Phenylcarbamates; Quinolines; Suicide; Sulfides; Sulfonamides; Tosyl Compounds; United States; United States Food and Drug Administration | 2011 |
[What helps for persistent symptoms of asthma during inhalative steroid therapy?].
Topics: Acetates; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adult; Albuterol; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Child; Cyclopropanes; Drug Therapy, Combination; Ethanolamines; Formoterol Fumarate; Humans; Hydroxyurea; Leukotriene Antagonists; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Respiratory Function Tests; Salmeterol Xinafoate; Sulfides; Treatment Failure | 2011 |
Membrane and inhibitor interactions of intracellular phospholipases A2.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Cell Membrane; Eukaryotic Cells; Gene Expression Regulation; Humans; Hydroxyurea; Lipoxygenase; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Phospholipases A2; Phospholipids; Prostaglandin-Endoperoxide Synthases; Signal Transduction | 2016 |
Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway.
Topics: Acetates; Adult; Animals; Cyclopropanes; Dermatitis, Atopic; Female; Forecasting; Humans; Hydroxyurea; Leukotriene Antagonists; Male; Molecular Targeted Therapy; Prostaglandin Antagonists; Quinolines; Severity of Illness Index; Sulfides; Treatment Outcome | 2018 |
Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management.
Topics: Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cromolyn Sodium; Disease Management; Glucocorticoids; Histamine; Histamine Antagonists; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Hydroxyurea; Interleukin-6; Leukotriene Antagonists; Leukotriene E4; Mastocytosis; Omalizumab; Prostaglandin D2; Tryptases | 2019 |
62 trial(s) available for zileuton and hydroxyurea
| Article | Year |
|---|---|
Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Male; Middle Aged; Time Factors | 1992 |
Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Evaluation; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Sigmoidoscopy | 1992 |
Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo.
Topics: Adolescent; Adult; Arachidonate 5-Lipoxygenase; Calcimycin; Chromatography, High Pressure Liquid; Double-Blind Method; Humans; Hydroxyurea; In Vitro Techniques; Leukotriene B4; Lipoxygenase Inhibitors; Male; Middle Aged; Radioimmunoassay | 1991 |
Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.
Topics: Double-Blind Method; Female; Histamine Release; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Leukotriene B4; Leukotrienes; Lipoxygenase Inhibitors; Male; Nasal Obstruction; Nasal Provocation Tests; Prostaglandin D2; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; Sneezing | 1990 |
Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.
Topics: Adolescent; Adult; Humans; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Male; Thromboxanes | 1991 |
Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients.
Topics: Adult; Allergens; Asthma; Double-Blind Method; Forced Expiratory Volume; Humans; Hydroxyurea; Leukotriene B4; Leukotriene E4; Lipoxygenase Inhibitors; Male; SRS-A; Time Factors | 1991 |
The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.
Topics: Asthma; Bronchial Provocation Tests; Bronchoconstriction; Calcimycin; Cold Temperature; Double-Blind Method; Eicosanoids; Humans; Humidity; Hydroxyurea; Lipoxygenase Inhibitors; Male | 1990 |
Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects.
Topics: Adult; Arachidonate 5-Lipoxygenase; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cold Temperature; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Single-Blind Method; Time Factors | 1995 |
Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Hydroxyurea; Kinetics; Lipoxygenase Inhibitors; Male; Mathematics; Middle Aged; Time Factors | 1995 |
Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
Topics: Adolescent; Adult; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Bronchoconstriction; Cross-Over Studies; Double-Blind Method; Forced Expiratory Volume; Humans; Hydroxyurea; Inflammation; Leukotriene E4; Leukotrienes; Lipoxygenase Inhibitors; Middle Aged | 1995 |
The effect of zileuton on antipyrine and indocyanine green disposition.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Double-Blind Method; Humans; Hydroxyurea; Indocyanine Green; Lipoxygenase Inhibitors; Male | 1995 |
A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotriene E4; Lipoxygenase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome | 1995 |
Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma.
Topics: Adult; Aspirin; Asthma; Blood Proteins; Chymases; Cross-Over Studies; Double-Blind Method; Eosinophil Granule Proteins; Female; Histamine; Humans; Hydroxyurea; Leukotrienes; Male; Mast Cells; Middle Aged; Nasal Mucosa; Ribonucleases; Serine Endopeptidases; Tryptases | 1994 |
The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Topics: Adult; Albuterol; Asthma; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male; Single-Blind Method | 1993 |
The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
Topics: Adult; Arachidonate 5-Lipoxygenase; Aspirin; Asthma; Bronchoconstriction; Double-Blind Method; Drug Hypersensitivity; Female; Forced Expiratory Volume; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male; Middle Aged | 1993 |
Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cross-Over Studies; Dinoprost; Dinoprostone; Double-Blind Method; Eosinophils; Humans; Hydroxyurea; Leukotriene B4; Leukotriene E4; Leukotrienes; Lipoxygenase Inhibitors; Lung; Lung Injury; Placebos; Prostaglandin D2; Prostaglandin-Endoperoxide Synthases; Proteins; Regression Analysis; Respiratory Hypersensitivity; Thromboxane B2 | 1995 |
Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Asthma; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Liver; Liver Function Tests; Male; Peak Expiratory Flow Rate; Quality of Life | 1996 |
Pharmacokinetic interactions between zileuton and prednisone.
Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Inflammatory Agents; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Prednisone | 1995 |
The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Digestive System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Endoscopy; Humans; Hydroxyurea; Intestinal Mucosa; Leukotriene B4; Lipoxygenase Inhibitors; Male; Naproxen; Thromboxane B2 | 1995 |
Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Circadian Rhythm; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Humans; Hydroxylation; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Male; Middle Aged; Stereoisomerism; Urea; White People | 1995 |
The pharmacokinetics of zileuton in healthy young and elderly volunteers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aging; Analysis of Variance; Chromatography, High Pressure Liquid; Coloring Agents; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hydroxylation; Hydroxyurea; Indocyanine Green; Lipoxygenase Inhibitors; Liver Circulation; Male; Reproducibility of Results; Sex Characteristics | 1995 |
The effect of food on the pharmacokinetics of zileuton.
Topics: Absorption; Adult; Analysis of Variance; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Eating; Fasting; Food-Drug Interactions; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Reproducibility of Results | 1995 |
Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Anticoagulants; Blood Coagulation; Blood Specimen Collection; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Prothrombin Time; Reproducibility of Results; Stereoisomerism; Warfarin | 1995 |
Effect of zileuton on theophylline pharmacokinetics.
Topics: Administration, Oral; Adult; Analysis of Variance; Bronchodilator Agents; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Half-Life; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Theophylline | 1995 |
Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Anticonvulsants; Chromatography, High Pressure Liquid; Cross-Over Studies; Double-Blind Method; Drug Interactions; Humans; Hydroxyurea; Linear Models; Lipoxygenase Inhibitors; Male; Phenytoin; Reproducibility of Results | 1995 |
The pharmacokinetics of single oral doses of zileuton 200 to 800mg, its enantiomers, and its metabolites, in normal healthy volunteers.
Topics: Absorption; Administration, Oral; Adult; Analysis of Variance; Biological Availability; Blood Proteins; Chromatography, High Pressure Liquid; Cross-Over Studies; Dose-Response Relationship, Drug; Glomerular Filtration Rate; Glucuronates; Half-Life; Humans; Hydroxylation; Hydroxyurea; Kidney Tubules, Proximal; Lipoxygenase Inhibitors; Male; Middle Aged; Protein Binding; Stereoisomerism; Urea | 1995 |
Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Blood Cell Count; Cardiotonic Agents; Cross-Over Studies; Digoxin; Double-Blind Method; Drug Interactions; Electrocardiography; Half-Life; Humans; Hydroxyurea; Isotope Labeling; Lipoxygenase Inhibitors; Male; Radioimmunoassay | 1995 |
The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Half-Life; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Sulfapyridine; Sulfasalazine | 1995 |
A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.
Topics: Adult; Antigens; Bronchoalveolar Lavage Fluid; Cell Count; Double-Blind Method; Eosinophils; Female; Humans; Hydroxyurea; Hypersensitivity; Leukotriene E4; Lipoxygenase Inhibitors; Male; Pneumonia; Pollen | 1996 |
Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor.
Topics: Adult; Albuterol; Anti-Asthmatic Agents; Asthma, Exercise-Induced; Bronchial Spasm; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Forced Expiratory Volume; Humans; Hydroxyurea; Inflammation Mediators; Leukotriene Antagonists; Leukotriene B4; Leukotriene C4; Leukotrienes; Lipoxygenase Inhibitors; Vital Capacity | 1996 |
Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Anti-Asthmatic Agents; Asthma; Bronchoconstriction; Double-Blind Method; Drug Therapy, Combination; Eosinophils; Female; Forced Expiratory Volume; Histamine Antagonists; Humans; Hydroxyurea; Leukocyte Count; Leukotrienes; Lipoxygenase Inhibitors; Liver Function Tests; Male; Middle Aged; Time Factors; Treatment Outcome | 1996 |
A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mesalamine; Middle Aged; Multivariate Analysis | 1997 |
The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Double-Blind Method; Drug Synergism; Electrocardiography; Histamine H1 Antagonists; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Terfenadine | 1997 |
Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers.
Topics: Adolescent; Adult; Circadian Rhythm; Cross-Over Studies; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Urea | 1997 |
Pharmacokinetics of zileuton and its metabolites in patients with renal impairment.
Topics: Adult; Aged; Female; Humans; Hydroxyurea; Kidney Diseases; Kidney Failure, Chronic; Kidney Function Tests; Lipoxygenase Inhibitors; Male; Middle Aged; Renal Dialysis | 1997 |
Drug interactions with zileuton.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Bronchodilator Agents; Double-Blind Method; Drug Interactions; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Theophylline; Warfarin | 1997 |
A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group.
Topics: Adult; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lung Volume Measurements; Male; Middle Aged; Severity of Illness Index; Theophylline; Time Factors; Treatment Outcome | 1998 |
Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Histamine; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Reference Values; Respiratory Function Tests; Sensitivity and Specificity; Water | 1997 |
Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
Topics: Adrenergic beta-Agonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Histamine; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotriene D4; Lipoxygenase Inhibitors; Male; Middle Aged; Peak Expiratory Flow Rate | 1998 |
The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma.
Topics: Adult; Airway Resistance; Asthma; Cross-Over Studies; Double-Blind Method; Female; Humans; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Male; Neutropenia; Oxygen; Platelet Activating Factor; Pulmonary Gas Exchange; Respiratory Mechanics; Ventilation-Perfusion Ratio | 1998 |
Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
Topics: Adolescent; Adult; Aged; Asthma; Double-Blind Method; Drug Administration Schedule; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Managed Care Programs; Middle Aged; Respiratory Function Tests; Respiratory System Agents; United States | 1997 |
Safety and clinical efficacy of zileuton in patients with chronic asthma.
Topics: Asthma; Chronic Disease; Disease Management; Forced Expiratory Volume; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Managed Care Programs; Safety; Treatment Outcome; United States | 1998 |
A pilot study examining the role of zileuton in atopic dermatitis.
Topics: Adult; Dermatitis, Atopic; Follow-Up Studies; Humans; Hydroxyurea; Leukotriene Antagonists; Patient Satisfaction; Pilot Projects | 1999 |
Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics.
Topics: Adult; Asthma; Bronchial Provocation Tests; Bronchoalveolar Lavage Fluid; Cytokines; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxyurea; Inflammation Mediators; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Male; Skin Tests | 2000 |
Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis.
Topics: Administration, Oral; Animals; Cross-Over Studies; Dermatitis, Atopic; Dog Diseases; Dogs; Double-Blind Method; Female; Hydroxyurea; Leukotriene Antagonists; Male; Pilot Projects; Treatment Outcome | 2001 |
Suppression of leukotriene B4 generation by ex-vivo neutrophils isolated from asthma patients on dietary supplementation with gammalinolenic acid-containing borage oil: possible implication in asthma.
Topics: Adult; Aged; Arthritis, Rheumatoid; Asthma; Dietary Supplements; Double-Blind Method; Fatty Acids; Female; gamma-Linolenic Acid; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Male; Middle Aged; Neutrophils; Plant Oils; Prospective Studies | 2004 |
The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
Topics: Acclimatization; Administration, Oral; Adult; Alaska; Altitude Sickness; Arachidonate 5-Lipoxygenase; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxyurea; Inflammation Mediators; Leukotriene E4; Lipoxygenase Inhibitors; Male; Middle Aged; Mountaineering; Oximetry; Premedication; Statistics as Topic; Treatment Outcome | 2005 |
Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects.
Topics: Adult; Animals; Bronchi; Bronchial Provocation Tests; Cytokines; Dust; Female; Humans; Hydroxyurea; Inhalation Exposure; Lipoxygenase Inhibitors; Male; Middle Aged; Nasal Lavage Fluid; Nitric Oxide; Respiratory Function Tests; Swine | 2006 |
Effect of leukotriene modifier drugs on the safety of oral aspirin challenges.
Topics: Acetates; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Asthmatic Agents; Aspirin; Asthma; Cyclopropanes; Desensitization, Immunologic; Drug Hypersensitivity; Female; Forced Expiratory Volume; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Lipoxygenase Inhibitors; Male; Middle Aged; Phenylcarbamates; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds; Treatment Outcome | 2006 |
Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: effects of treatment with zileuton.
Topics: Adult; Arachidonate 5-Lipoxygenase; Chromatography, High Pressure Liquid; Double-Blind Method; Evaluation Studies as Topic; Female; Flow Cytometry; Humans; Hydroxyurea; Leukocytes, Mononuclear; Leukotriene Antagonists; Leukotriene B4; Male; Middle Aged; Saliva | 2007 |
Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma.
Topics: Adolescent; Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Beclomethasone; Double-Blind Method; Drug Therapy, Combination; Forced Expiratory Volume; Glucocorticoids; Humans; Hydroxyurea; Middle Aged; Peak Expiratory Flow Rate; Severity of Illness Index; Single-Blind Method | 2007 |
The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Asthma; Child; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glucocorticoids; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Peak Expiratory Flow Rate; Quality of Life; Tablets | 2007 |
Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Child; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Hydroxyurea; Inhalation; Middle Aged; Tablets; Treatment Outcome | 2007 |
Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Asthma; Chemical and Drug Induced Liver Injury; Chronic Disease; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Liver Function Tests; Male; Prospective Studies | 2007 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci.
Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Cysteine; Female; Forced Expiratory Volume; Genotype; Humans; Hydroxyurea; Leukotriene Antagonists; Lipoxygenase Inhibitors; Male; Middle Aged; Polymorphism, Single Nucleotide; Quinolines; Receptors, Leukotriene; Sulfides | 2009 |
Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 microg/Salmeterol 50 microg.
Topics: Adult; Albuterol; Androstadienes; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Drug Therapy, Combination; Eosinophils; Female; Fluticasone; Humans; Hydroxyurea; Juniperus; Leukocyte Count; Male; Middle Aged; Nitric Oxide; Prospective Studies; Pulmonary Alveoli; Respiratory Function Tests; Respiratory System; Salmeterol Xinafoate; Spirometry | 2009 |
Influence of leukotriene biosynthesis inhibition on heart rate in patients with atrial fibrillation.
Topics: Aged; Arachidonate 5-Lipoxygenase; Atrial Fibrillation; Female; Heart Rate; Humans; Hydroxyurea; Leukotriene Antagonists; Male; Middle Aged; Placebos | 2010 |
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
Topics: Aged; Biomarkers; Double-Blind Method; Drug Administration Schedule; Female; Hospitalization; Humans; Hydroxyurea; Length of Stay; Leukotriene B4; Leukotriene E4; Lipoxygenase Inhibitors; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Treatment Failure; Treatment Outcome | 2011 |
Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Topics: Adult; Arachidonate 5-Lipoxygenase; Biomarkers; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Hydroxyurea; Leukotriene E4; Lipoxygenase Inhibitors; Male; Maximum Tolerated Dose; Prognosis; Prostaglandins; Pyrazoles; Smoking; Sulfonamides; Tandem Mass Spectrometry | 2013 |
Genome-wide association study of leukotriene modifier response in asthma.
Topics: Acetates; Anti-Asthmatic Agents; Asthma; Cohort Studies; Cyclopropanes; Gene-Environment Interaction; Genetic Loci; Genome-Wide Association Study; Genotype; Humans; Hydroxyurea; Leukotrienes; Phenotype; Polymorphism, Single Nucleotide; Quinolines; Sulfides | 2016 |
Zileuton for Pruritus in Sjögren-Larsson Syndrome: A Randomized Double-blind Placebo-controlled Crossover Trial.
Topics: Adolescent; Adult; Antipruritics; Child; Double-Blind Method; Female; Humans; Hydroxyurea; Male; Netherlands; Pruritus; Sjogren's Syndrome; Time Factors; Treatment Outcome; Young Adult | 2016 |
273 other study(ies) available for zileuton and hydroxyurea
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
Topics: Biological Assay; Humans; Inactivation, Metabolic; Metabolic Clearance Rate; Mitochondria; Mitochondrial Proteins; Oxidation-Reduction; Oxidoreductases; Oximes; Substrate Specificity | 2020 |
Nitroxide metabolites from alkylhydroxylamines and N-hydroxyurea derivatives resulting from reductive inhibition of soybean lipoxygenase.
Topics: Benzeneacetamides; Electron Spin Resonance Spectroscopy; Free Radicals; Glycine max; Hydroxamic Acids; Hydroxylamines; Hydroxyurea; Lipoxygenase Inhibitors; Molecular Structure; Nitrogen Oxides; Oxidation-Reduction; Structure-Activity Relationship | 1992 |
Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Benzopyrans; Carrier Proteins; Free Radical Scavengers; Gastric Mucosa; Hydroxyurea; Indoles; Indomethacin; Leukotriene Antagonists; Leukotriene B4; Leukotrienes; Lipoxygenase Inhibitors; Male; Masoprocol; Membrane Proteins; Organic Chemicals; Permeability; Phenylcarbamates; Propionates; Quinolines; Rats; Rats, Inbred Strains; Receptors, Immunologic; Receptors, Leukotriene; Receptors, Leukotriene B4; Single-Blind Method; Stomach Ulcer; Sulfonamides; Tetrazoles; Tosyl Compounds | 1992 |
The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.
Topics: Administration, Oral; Animals; Antigens; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Bronchoconstriction; Calcimycin; Dose-Response Relationship, Drug; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Sheep | 1992 |
Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Bronchoconstriction; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Guinea Pigs; Hydroxyurea; Inflammation; Knee Joint; Leukotriene B4; Lipoxygenase Inhibitors; Macrophages; Male; Mice; Oxidation-Reduction; Pyrans; Quinolones; Rabbits; Rats; Thromboxane B2 | 1992 |
Effect of BI-L-239, A-64077 and MK-886 on leukotriene B4 synthesis by chopped guinea pig lung and on antigen-induced tracheal contraction in vitro.
Topics: Animals; Guinea Pigs; Hydroxyurea; In Vitro Techniques; Indoles; Leukotriene B4; Lipoxygenase Inhibitors; Lung; Male; Muscle Contraction; Muscle, Smooth; Ovalbumin; Phenols; Trachea | 1992 |
Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity.
Topics: Arachidonate 5-Lipoxygenase; Arachidonic Acid; Calcimycin; Cell Compartmentation; Cell Membrane; Cytosol; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; In Vitro Techniques; Indoles; Leukotrienes; Neutrophils; Substrate Specificity | 1992 |
Kinetics and mechanism of degradation of Zileuton, a potent 5-lipoxygenase inhibitor.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Hydrogen-Ion Concentration; Hydrolysis; Hydroxyurea; Kinetics; Lipoxygenase Inhibitors; Oxidation-Reduction; Temperature | 1992 |
Enantiomeric activation of glucuronidation in dog hepatic microsomes.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Glucuronates; Hydroxyurea; Kinetics; Lipoxygenase Inhibitors; Microsomes, Liver; Stereoisomerism | 1992 |
Inhibition of leukotriene B4 biosynthesis by disulfiram and A-64077 during carrageenan-induced pleurisy in the rat.
Topics: Aldehyde Dehydrogenase; Animals; Carrageenan; Colitis, Ulcerative; Disulfiram; Exudates and Transudates; Humans; Hydroxyurea; In Vitro Techniques; Leukocytes; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pleurisy; Rats; Rats, Inbred Strains | 1991 |
Therapeutic approaches to reduce airway inflammation.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Blood Platelets; Bronchi; Cell Adhesion Molecules; Humans; Hydroxyurea; Intercellular Adhesion Molecule-1; Interleukin-5; Lipoxygenase Inhibitors | 1991 |
Pharmacologic evaluation of A23187-induced contractions of three distinct preparations of guinea pig lung parenchymal strips.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Calcimycin; Drug Interactions; Guinea Pigs; Histamine; Hydroxyurea; In Vitro Techniques; Indomethacin; Lung; Male; Muscle Contraction; Muscle, Smooth; Prostaglandin Endoperoxides, Synthetic; Pyrilamine; SRS-A | 1992 |
Inhibition of leukotriene biosynthesis in the rat peritoneal cavity.
Topics: Administration, Oral; Anaphylaxis; Animals; Disease Models, Animal; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Male; Peritoneal Cavity; Rats; Rats, Inbred Strains; SRS-A | 1991 |
5-lipoxygenase inhibitory activity of zileuton.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Chromatography, High Pressure Liquid; Dogs; Edema; Haplorhini; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mice; Rats; Rats, Inbred Strains; Species Specificity | 1991 |
Asthma: the molecular light at the end of the tracheal tunnel.
Topics: Asthma; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Propionates; Quinolines | 1991 |
Selective 5-lipoxygenase inhibition in ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arachidonate Lipoxygenases; Colitis, Ulcerative; Dialysis; Dinoprostone; Drug Evaluation; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Middle Aged; Recurrence; Time Factors | 1990 |
Arachidonate 5-lipoxygenase inhibition and acute renal allograft rejection.
Topics: Animals; Dogs; Graft Rejection; Hydroxyurea; Kidney Transplantation; Lipoxygenase Inhibitors; Transplantation, Autologous; Transplantation, Homologous | 1991 |
From the National Institutes of Health.
Topics: Arthritis, Juvenile; Asthma; CD4 Antigens; Cells, Cultured; Exotoxins; HIV-1; HLA Antigens; Humans; Hydroxyurea; Immunotoxins; Lipoxygenase Inhibitors; National Institutes of Health (U.S.); Recombinant Proteins; Respiratory Hypersensitivity; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal; T-Lymphocytes; United States | 1991 |
Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases.
Topics: Aminosalicylic Acids; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Dexamethasone; Endotoxins; Humans; Hydroxyurea; In Vitro Techniques; Inflammatory Bowel Diseases; Interleukin-1; Interleukin-6; Leukocytes, Mononuclear; Mesalamine; Sulfapyridine; Tumor Necrosis Factor-alpha | 1995 |
Peptidoleukotriene (pLT) release from guinea pig lung mast cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Female; Guinea Pigs; Histamine Release; Hydroxyurea; In Vitro Techniques; Leukotrienes; Lung; Mast Cells | 1994 |
Leukotrienes and alpha-naphthylisothiocyanate-induced liver injury.
Topics: 1-Naphthylisothiocyanate; Acetamides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcimycin; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Glutathione; Hydroxyurea; Indoles; Inflammation; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Liver; Liver Diseases; Male; Phenyl Ethers; Rats; Rats, Sprague-Dawley | 1995 |
Dose-dependent mediation of leukotriene D4-induced airway microvascular leakage and bronchoconstriction in the guinea pig.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Bridged Bicyclo Compounds, Heterocyclic; Bronchi; Bronchoconstriction; Capillary Permeability; Chromones; Fatty Acids, Unsaturated; Furans; Guinea Pigs; Hydrazines; Hydroxyurea; Leukotriene D4; Lipoxygenase Inhibitors; Lung; Male; Meclofenamic Acid; Plasma; Prostaglandin Endoperoxides, Synthetic; Pyrilamine; Receptors, Thromboxane; SRS-A; Thromboxane A2; Trachea; Vasoconstrictor Agents | 1995 |
Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Division; Cell Line; Cell Survival; Dog Diseases; Dogs; Drug Screening Assays, Antitumor; Hydroxyurea; Indomethacin; Melanoma; Piroxicam; Sarcoma; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1995 |
Pharmacologic modulation of the influence of the epithelium on immunologic- and nonimmunologic-induced histamine release and contraction in guinea pig superfused tracheal strips.
Topics: Animals; Epithelium; Female; Guinea Pigs; Histamine Release; Hydroxyurea; In Vitro Techniques; Indazoles; Indomethacin; Muscle Contraction; Ovalbumin; Pyrilamine; Trachea; Tubocurarine | 1993 |
Cyproheptadine-induced attenuation of type-I immediate-hypersensitivity reactions of airway smooth muscle from immune-sensitized cats.
Topics: Airway Resistance; Analysis of Variance; Animals; Ascaris suum; Cat Diseases; Cats; Cyproheptadine; Female; Hydroxyurea; In Vitro Techniques; Lipoxygenase Inhibitors; Male; Muscle, Smooth; Respiratory Hypersensitivity; Serotonin | 1995 |
Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Chromosomes, Human; Glucuronates; Humans; Hydroxyurea; In Vitro Techniques; Microsomes, Liver; Stereoisomerism | 1995 |
Properties of LTA4 synthase in human neutrophil preparations.
Topics: Arachidonate 5-Lipoxygenase; Calcimycin; Cell Membrane; Cytosol; Humans; Hydroxyurea; Kinetics; Lipoxygenase Inhibitors; Neutrophils | 1995 |
Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Base Sequence; Cell Line; Chloramphenicol O-Acetyltransferase; Cyclooxygenase Inhibitors; DNA Primers; Gene Expression; HeLa Cells; Humans; Hydroxyurea; Interleukin-6; Ionomycin; Kinetics; Lipoxygenase Inhibitors; Mice; Molecular Sequence Data; Naproxen; NF-kappa B; Oligodeoxyribonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-myc; Pyrazoles; Recombinant Proteins; Tetradecanoylphorbol Acetate; Transfection; Tumor Cells, Cultured | 1995 |
Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Haplorhini; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Mice; Rats; Stereoisomerism | 1995 |
Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats.
Topics: Animals; Colitis; Colon; Eicosanoids; Hydroxyurea; Inflammatory Bowel Diseases; Leukocytes; Lipoxygenase Inhibitors; Male; Peroxidase; Rats; Rats, Wistar; Sulfasalazine; Trinitrobenzenesulfonic Acid | 1993 |
Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005.
Topics: 5-Lipoxygenase-Activating Proteins; Administration, Oral; Animals; Benzoquinones; Bronchoconstriction; Carrier Proteins; Guinea Pigs; Hydroxyurea; In Vitro Techniques; Indoles; Injections, Intravenous; Leukotriene Antagonists; Lipoxygenase Inhibitors; Male; Membrane Proteins; Ovalbumin; Pyrans; Quinolines; Quinolones; Trachea | 1994 |
Eosinophil 15-lipoxygenase is a leukotriene A4 synthase.
Topics: Arachidonate 15-Lipoxygenase; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Cell-Free System; Cytosol; Dose-Response Relationship, Drug; Eosinophils; Granulocytes; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Leukotriene A4; Leukotrienes; Lipoxygenase Inhibitors; Models, Chemical; Neutrophils; Recombinant Proteins | 1994 |
Intrinsic 5-lipoxygenase activity is required for neutrophil responsivity.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Adhesion; Chemotaxis, Leukocyte; Cytochrome c Group; Dose-Response Relationship, Drug; Humans; Hydroxyurea; In Vitro Techniques; Indoles; Interleukin-8; Kinetics; Leukotriene Antagonists; Leukotriene B4; Lipoxygenase Inhibitors; Lung; Male; Neutrophils; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Superoxides; Tetradecanoylphorbol Acetate | 1994 |
The 5-lipoxygenase inhibitory activity of zileuton in in vitro and in vivo models of antigen-induced airway anaphylaxis.
Topics: Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoconstriction; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Guinea Pigs; Humans; Hydroxyurea; Indazoles; Lipoxygenase Inhibitors; Male; Meclofenamic Acid; Muscle Contraction; Muscle, Smooth; Pyrilamine; SRS-A; Trachea | 1994 |
Preclinical and clinical activity of zileuton and A-78773.
Topics: Animals; Bronchial Spasm; Guinea Pigs; Hydroxyurea; Inflammation; Leukotriene B4; Lipoxygenase Inhibitors; Lung; Male; Rats | 1993 |
Role of cysteinyl-leukotrienes and histamine in mediating intrinsic tone in isolated human bronchi.
Topics: Bronchi; Chlorpheniramine; Dicarboxylic Acids; Female; Histamine; Humans; Hydroxyurea; In Vitro Techniques; Indazoles; Isometric Contraction; Isotonic Solutions; Leukotriene D4; Lipoxygenase Inhibitors; Male; Middle Aged; Muscle Tonus; Muscle, Smooth; Pyrilamine; SRS-A | 1994 |
Use of a continuous assay of oxygen consumption to evaluate the pharmacology of 5-lipoxygenase inhibitors.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Animals; Drug Evaluation, Preclinical; Humans; Hydroxyurea; Imidazoles; In Vitro Techniques; Leukotriene B4; Lipoxygenase Inhibitors; Monocytes; Oxygen Consumption; Rats; Tumor Cells, Cultured | 1993 |
Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Topics: Animals; Calcimycin; Chromatography, High Pressure Liquid; Depression, Chemical; Dogs; Dose-Response Relationship, Drug; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotriene E4; Leukotrienes; Lipoxygenase Inhibitors; Male; Quinolines | 1993 |
Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury.
Topics: Animals; Arachidonate 5-Lipoxygenase; Dogs; Hydroxyurea; Intestinal Mucosa; Intestines; Leukotriene B4; Leukotrienes; Lipoxygenase Inhibitors; Models, Biological; Neutrophils; Reperfusion Injury | 1994 |
The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor.
Topics: Anaphylaxis; Animals; Biological Availability; Blood Proteins; Dogs; Half-Life; Humans; Hydroxyurea; Leukotriene B4; Leukotrienes; Lipoxygenase Inhibitors; Macaca fascicularis; Male; Microsomes, Liver; Protein Binding; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 1993 |
Effect of 5-lipoxygenase inhibitors on the anti-IgE-induced contraction of passively sensitized human bronchus in vitro.
Topics: Antibodies, Anti-Idiotypic; Bronchoconstriction; Humans; Hydroxyurea; Immunoglobulin E; In Vitro Techniques; Indoles; Leukotrienes; Lipoxygenase Inhibitors; Pyrilamine | 1993 |
Effect of 5-lipoxygenase inhibitors on in situ LTB4 biosynthesis following calcium ionophore stimulation in the rat pleural cavity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcimycin; Carrageenan; Dose-Response Relationship, Drug; Hydroxyurea; Indoles; Leukotriene B4; Lipoxygenase Inhibitors; Pleura; Radioimmunoassay; Rats | 1993 |
Inhibition of endotoxin-induced hypothermia and serum TNF-alpha levels in CD-1 mice by various pharmacological agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Endotoxins; Hydroxyurea; Hypothermia; Lipopolysaccharides; Lipoxygenase Inhibitors; Male; Mice; Naphthaleneacetic Acids; Quinolines; Shock, Septic; Tromethamine; Tumor Necrosis Factor-alpha | 1993 |
Irreversible inactivation of 5-lipoxygenase by leukotriene A4. Characterization of product inactivation with purified enzyme and intact leukocytes.
Topics: Arachidonate 5-Lipoxygenase; Cell Differentiation; Cell Line; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Kinetics; Leukemia, Promyelocytic, Acute; Leukocytes; Leukotriene A4; Lipoxygenase Inhibitors; Neutrophils; Tumor Cells, Cultured | 1994 |
Leukotrienes mediate antigen-induced airway hyper-reactivity in guinea pigs.
Topics: Acetophenones; Animals; Antigens; Bronchoconstriction; Eosinophilia; Guinea Pigs; Hydroxyurea; Indoles; Leukotriene D4; Leukotrienes; Lipoxygenase Inhibitors; Male; Naphthaleneacetic Acids; Quinolines; Tetrazoles | 1994 |
LTB4-induced transient neutropenia in the rat: a model for evaluating efficacy and bioavailability of LTB4 receptor antagonists.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Dexamethasone; Hydroxyurea; Indomethacin; Leukocyte Count; Leukotriene B4; Male; Models, Biological; Naproxen; Neutropenia; Neutrophils; Rats; Rats, Sprague-Dawley; Receptors, Leukotriene B4 | 1993 |
WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
Topics: Administration, Oral; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Asthma; Female; Guinea Pigs; Humans; Hydroxyurea; Indoles; Leukocytes; Leukotriene B4; Lipoxygenase Inhibitors; Macrophages; Male; Mice; Naphthaleneacetic Acids; Prostaglandin-Endoperoxide Synthases; Quinolines; Rabbits; Rats; Rats, Wistar | 1993 |
Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcimycin; Disease Models, Animal; Drug Evaluation, Preclinical; Eicosanoids; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Male; Pleurisy; Prostaglandins; Pyrans; Quinolones; Rats; Rats, Sprague-Dawley | 1993 |
Oxidative modification of low-density lipoproteins by mesangial cells.
Topics: Antioxidants; Arachidonic Acid; Butylated Hydroxytoluene; Catalase; Cell Division; Cells, Cultured; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Deferoxamine; DNA Replication; Glomerular Mesangium; Glomerulosclerosis, Focal Segmental; Humans; Hydroxyurea; Indomethacin; Ketoconazole; Lipoproteins, LDL; Lipoxygenase Inhibitors; Masoprocol; Oxidation-Reduction; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 1993 |
Criteria for the identification of non-redox inhibitors of 5-lipoxygenase.
Topics: Arachidonate 5-Lipoxygenase; Benzeneacetamides; Benzofurans; Enzyme Inhibitors; Humans; Hydroxamic Acids; Hydroxyurea; Indoles; Leukotrienes; Lipid Peroxides; Lipoxygenase Inhibitors; Naphthalenes; Oxidation-Reduction; Thiazoles | 1993 |
Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues.
Topics: Acetophenones; Animals; Guinea Pigs; Hydroxyurea; In Vitro Techniques; Indoles; Leukotriene Antagonists; Lipoxygenase Inhibitors; Lung; Male; Muscle Contraction; Muscle, Smooth; Naphthaleneacetic Acids; Quinolines; SRS-A; Tetrazoles; Trachea | 1993 |
Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
Topics: Animals; Antigens; Blood Vessels; Bronchoalveolar Lavage Fluid; Bronchoconstriction; Calcimycin; Guinea Pigs; Humans; Hydroxyurea; Indomethacin; Lipoxygenase Inhibitors; Male; Pyrans; Quinolones; Rats; Skin | 1995 |
CGS 26529: the biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action.
Topics: Animals; Dogs; Female; Guinea Pigs; Humans; Hydroxyurea; In Vitro Techniques; Injections, Intravenous; Isoquinolines; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred AKR; Pleurisy; Rats; Rats, Sprague-Dawley; Tetrahydroisoquinolines | 1995 |
Pulmonary pharmacology of WAY-126299A: a dual-acting 5-lipoxygenase inhibitor and leukotriene D4 antagonist.
Topics: Acetamides; Anesthesia; Animals; Benzothiazoles; Bronchoconstriction; Guinea Pigs; Humans; Hydroxyurea; In Vitro Techniques; Leukotriene D4; Lipoxygenase Inhibitors; Lung; Naphthaleneacetic Acids; Quinolines; Respiration, Artificial; Thiazoles | 1995 |
Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Base Sequence; Binding, Competitive; Cell Movement; E-Selectin; Hydroxyurea; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Lipoxygenase Inhibitors; Macrophage-1 Antigen; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Naproxen; Neutrophils; Pyrazoles; Skin; Tumor Necrosis Factor-alpha | 1996 |
Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Bronchoconstriction; Guinea Pigs; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Macrophages; Mice; Molecular Structure; Monocytes; Oxazoles; Rats; Structure-Activity Relationship; Thiazoles | 1996 |
Lipid mediators in the rat retina: light exposure and trauma elicit leukotriene B4 release in vitro.
Topics: Animals; Arachidonate 5-Lipoxygenase; Eicosanoids; Enzyme Activation; Hydroxyurea; Leukotriene B4; Light; Lipid Metabolism; Lipoxygenase Inhibitors; Male; Radiation Injuries, Experimental; Radioimmunoassay; Rats; Retina; Rhodopsin | 1995 |
The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Chronic Disease; Disease Models, Animal; Drug Combinations; Exudates and Transudates; Female; Hydroxyurea; Inflammation; Leukotriene B4; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Naproxen; Prostaglandin-Endoperoxide Synthases; Quinolines; Time Factors; Zymosan | 1996 |
Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity.
Topics: 1-Naphthylisothiocyanate; Animals; Azepines; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Male; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Triazoles | 1996 |
Determination of a new 5-lipoxygenase inhibitor, zileuton, and its inactive N-dehydroxylated metabolite in plasma by high performance liquid chromatography.
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Haplorhini; Humans; Hydroxylation; Hydroxyurea; Lipoxygenase Inhibitors; Rats; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stereoisomerism; Urea | 1995 |
In vitro plasma protein binding of zileuton and its N-dehydroxylated metabolite.
Topics: Adult; Anti-Allergic Agents; Anti-Inflammatory Agents; Anticoagulants; Blood Proteins; Chromatography, High Pressure Liquid; Drug Interactions; Female; Hematocrit; Humans; Hydroxylation; Hydroxyurea; Ibuprofen; In Vitro Techniques; Isotope Labeling; Lipoxygenase Inhibitors; Male; Naproxen; Prednisolone; Protein Binding; Salicylates; Stereoisomerism; Terfenadine; Theophylline; Warfarin | 1995 |
The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.
Topics: Administration, Oral; Adult; Aging; Blood Proteins; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Glucuronates; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Liver Cirrhosis; Male; Middle Aged; Protein Binding | 1995 |
Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193.
Topics: Cytochrome P-450 Enzyme System; Humans; Hydroxylation; Hydroxyurea; In Vitro Techniques; Isoenzymes; Lipoxygenase Inhibitors; Microsomes, Liver; Propranolol; Theophylline; Urea | 1995 |
Hepatic peroxisomal and drug metabolizing activity in CD-1 mice after oral treatment with a novel 5-lipoxygenase inhibitor.
Topics: Administration, Oral; Animals; Body Weight; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Female; Hepatomegaly; Hydroxyurea; Isoenzymes; Lipoxygenase Inhibitors; Liver; Male; Mice; Mice, Inbred Strains; Microbodies; Microsomes, Liver; Organ Size | 1996 |
Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors.
Topics: Animals; Benzofurans; Enzyme-Linked Immunosorbent Assay; Hip Joint; Humans; Hydroxyurea; Indoles; Interleukin-1; Knee Joint; Lipoxygenase Inhibitors; Naphthalenes; Organ Culture Techniques; Oxindoles; Pyrazoles; Quinolines; Structure-Activity Relationship; Swine; Synovial Membrane; Tarsus, Animal; Thiazoles; Thiophenes | 1996 |
Determination of 1-benzo[b]thien-2-ylethanone and related impurities by high performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Hydroxyurea; Lipoxygenase Inhibitors | 1996 |
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoquinones; Blood Platelets; Cells, Cultured; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Methacrylates; Molecular Structure; Neutrophils; Pyridines; Rats; Structure-Activity Relationship; Thromboxane B2; Thromboxane-A Synthase | 1996 |
Inhibition of tumour growth by lipoxygenase inhibitors.
Topics: Adenocarcinoma; Administration, Oral; Analysis of Variance; Animals; Benzeneacetamides; Cell Division; Colonic Neoplasms; Hydroxamic Acids; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mice; Neoplasm Transplantation; Treatment Outcome; Tumor Cells, Cultured | 1996 |
The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Hydroxyurea; Intestinal Mucosa; Leukocyte Count; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mitomycin; Neutrophils; Peroxidase; Rats; Rats, Sprague-Dawley | 1996 |
The effect of 5-lipoxygenase inhibition on Ascaris antigen (Ag)-induced responses in atopic monkeys.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Helminth; Ascaris suum; Bronchoalveolar Lavage Fluid; Hydroxyurea; Inflammation; Leukocyte Count; Lipoxygenase Inhibitors; Macaca fascicularis; Male; Neutrophils; Pyrans; Quinolones | 1996 |
Phospholipase A2 is involved in the mechanism of activation of neutrophils by polychlorinated biphenyls.
Topics: Animals; Arachidonic Acid; Aroclors; Aspirin; Cyclooxygenase Inhibitors; Hydroxyurea; In Vitro Techniques; Lipoxygenase Inhibitors; Male; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Phospholipases A; Phospholipases A2; Polychlorinated Biphenyls; Quinacrine; Rats; Superoxides; Terpenes; Tetradecanoylphorbol Acetate | 1996 |
Pharmacological modulation of eosinophil influx into the lungs of Brown Norway rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar Lavage Fluid; Calcimycin; Dextrans; Eosinophils; Hydroxyurea; Ionophores; Leukotriene B4; Leukotriene C4; Lipoxygenase Inhibitors; Male; Pulmonary Eosinophilia; Rats; Theophylline | 1996 |
Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis; Colon; Eicosanoids; Female; Hydroxyurea; Lipoxygenase Inhibitors; Mesalamine; Radioimmunoassay; Random Allocation; Rats; Rats, Sprague-Dawley; Trinitrobenzenesulfonic Acid | 1996 |
Depletion of human monocyte 85-kDa phospholipase A2 does not alter leukotriene formation.
Topics: Arachidonic Acids; Binding Sites; Calcimycin; Enzyme Inhibitors; Humans; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Molecular Weight; Monocytes; Oligonucleotides, Antisense; Phagocytosis; Phospholipases A; Phospholipases A2; Sulfonamides; Zymosan | 1997 |
Zileuton for asthma.
Topics: Adolescent; Adult; Asthma; Child; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Humans; Hydroxyurea; Intestinal Absorption; Leukotrienes; Lipoxygenase Inhibitors; Propranolol; Theophylline; Warfarin | 1997 |
Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism.
Topics: Animals; Cell Movement; Chemotaxis, Leukocyte; Eosinophils; Guinea Pigs; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotriene B4; Leukotriene D4; Lipoxygenase Inhibitors; Male; Membrane Proteins; N-Formylmethionine Leucyl-Phenylalanine; Phenylcarbamates; Receptors, Leukotriene; Receptors, Leukotriene B4; Sulfonamides; Tosyl Compounds; Trachea | 1997 |
Effects of the 5-lipoxygenase inhibitor A-64077 on intestinal hypothermic organ preservation injury.
Topics: Animals; Cryopreservation; Dinoprostone; Dogs; Hydroxyurea; Ileum; Leukotriene B4; Lipoxygenase Inhibitors; Organ Preservation; Peroxidase | 1997 |
Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration.
Topics: Administration, Oral; Alanine Transaminase; Animals; Azepines; Blood Platelets; Chemical and Drug Induced Liver Injury; Female; Fibrinogen; Hydroxyurea; Injections, Intraperitoneal; Injections, Intravenous; Leukotrienes; Lipopolysaccharides; Lipoxygenase Inhibitors; Liver; Liver Diseases; Necrosis; Neutrophils; Platelet Activating Factor; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Thrombocytopenia; Triazoles | 1997 |
Inherent tone of human bronchus: role of eicosanoids and the epithelium.
Topics: Adult; Aged; Bronchi; Carbachol; Cyclooxygenase Inhibitors; Eicosanoids; Epithelium; Female; Humans; Hydroxyurea; In Vitro Techniques; Indomethacin; Lipoxygenase Inhibitors; Male; Middle Aged; Muscle Tonus | 1997 |
Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.
Topics: Animals; Glucuronosyltransferase; Half-Life; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Macaca fascicularis; Metabolic Clearance Rate; Microsomes, Liver; Structure-Activity Relationship | 1997 |
Effect of mast cell deficiency and leukotriene inhibition on the influx of eosinophils induced by eotaxin.
Topics: Animals; Chemokine CCL11; Chemokines, CC; Cytokines; Eosinophils; Hydroxyurea; Injections, Intraperitoneal; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Mast Cells; Mice; Mice, Inbred BALB C; Peritoneal Cavity | 1997 |
Capacity for repeatable leukotriene generation after transient stimulation of mast cells and macrophages.
Topics: Animals; Arachidonate 5-Lipoxygenase; Biological Transport; Calcimycin; Cell Membrane; Enzyme Activation; Female; Hydroxyurea; Interphase; Leukemia, Basophilic, Acute; Leukotrienes; Lipoxygenase Inhibitors; Macrophages, Alveolar; Mast Cells; Rats; Rats, Wistar; Tumor Cells, Cultured | 1998 |
The relevance of resting tension to responsiveness and inherent tone of human bronchial smooth muscle.
Topics: Adult; Aged; Aged, 80 and over; Bronchi; Bronchodilator Agents; Carbachol; Electric Stimulation; Humans; Hydroxyurea; In Vitro Techniques; Isoproterenol; Lipoxygenase Inhibitors; Middle Aged; Muscle Tonus; Muscle, Smooth | 1998 |
Aqueous stability of SB 210661: kinetics and primary degradation mechanisms of an N-hydroxyurea-containing 5-lipoxygenase inhibitor.
Topics: Benzofurans; Drug Stability; Hydrogen-Ion Concentration; Hydroxyurea; Kinetics; Lipoxygenase Inhibitors; Urea; Water | 1998 |
Formulation development of sustained-release hydrophilic matrix tablets of zileuton.
Topics: Biological Availability; Chemistry, Pharmaceutical; Compressive Strength; Delayed-Action Preparations; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Osmolar Concentration; Polymers; Rotation; Solubility; Surface-Active Agents; Tablets; Viscosity; Water | 1997 |
Antileukotrienes in chronic urticaria.
Topics: Adult; Chronic Disease; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Male; Phenylcarbamates; Sulfonamides; Tosyl Compounds; Urticaria | 1998 |
The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Granuloma; Hydroxyurea; Inflammation Mediators; Leukotrienes; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Phenanthridines; Phospholipases A; Phospholipases A2; Platelet Activating Factor; Sulfonamides; Triazines | 1998 |
Leukotriene B4 mediates histamine induction of NF-kappaB and IL-8 in human bronchial epithelial cells.
Topics: Bronchi; Cell Line; Cell Line, Transformed; Epithelial Cells; Histamine; Humans; Hydroxyurea; Indoles; Interleukin-8; Leukotriene B4; Lipoxygenase Inhibitors; NF-kappa B; Phospholipases A; Phospholipases A2; Polymerase Chain Reaction; Quinolines; RNA, Messenger; Transfection | 1998 |
Allergen-stimulated leukotriene B4 and interleukin-8 levels in patients with asthma and allergic rhinitis-modulation by a lipid pathway inhibitor.
Topics: Adult; Aged; Allergens; Asthma; Female; Humans; Hydroxyurea; Interleukin-8; Leukocytes, Mononuclear; Leukotriene B4; Lipoxygenase Inhibitors; Male; Middle Aged; Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Seasonal | 1998 |
Successful treatment of chronic urticaria with leukotriene antagonists.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Controlled Clinical Trials as Topic; Double-Blind Method; Humans; Hydroxyurea; Leukotriene Antagonists; Male; Urticaria | 1998 |
Mechanism of pyocyanin- and 1-hydroxyphenazine-induced lung neutrophilia in sheep airways.
Topics: Animals; Bronchoalveolar Lavage Fluid; Chemotaxis, Leukocyte; Female; Hydroxyurea; In Vitro Techniques; Interleukin-8; Leukotriene B4; Lung; Macrophages, Alveolar; Neutrophils; Phenazines; Pseudomonas aeruginosa; Pyocyanine; Sheep | 1998 |
In vivo correlation of neutrophil receptor expression, ischemia-reperfusion injury, and selective 5-lipoxygenase inhibition in guinea pigs.
Topics: Animals; CD18 Antigens; Female; Guinea Pigs; Hydroxyurea; Lipoxygenase Inhibitors; Neutrophil Activation; Neutrophils; Receptors, Cell Surface; Reperfusion Injury; Skin; Wound Healing | 1998 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Aged; Albuterol; Asthma; Bone Density; Bronchial Spasm; Bronchodilator Agents; Child; Child, Preschool; Choice Behavior; Cromolyn Sodium; Cyclopropanes; Exercise; Female; Growth; Humans; Hydroxyurea; Indoles; Infant, Newborn; Ipratropium; Lactation; Leukotriene Antagonists; Phenylcarbamates; Pregnancy; Pregnancy Complications; Quinolines; Salmeterol Xinafoate; Sulfides; Sulfonamides; Tachycardia; Theophylline; Tosyl Compounds | 1999 |
The effects of multiple dosing with zileuton on antigen-induced responses in sheep.
Topics: Airway Resistance; Animals; Asthma; Bronchial Provocation Tests; Disease Models, Animal; Drug Administration Schedule; Female; Hydroxyurea; Leukotriene Antagonists; Random Allocation; Sheep | 1998 |
WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood.
Topics: Animals; Binding Sites; Dose-Response Relationship, Drug; Eicosanoids; Guinea Pigs; Humans; Hydroxyurea; Indoles; Leukocytes; Leukotriene Antagonists; Lipoxygenase Inhibitors; Male; Naphthaleneacetic Acids; Neutrophils; Quinolines; Rats; Serum Albumin | 1999 |
Selective effects of antileukotrienes on leukotriene and histamine release in human dispersed lung cells.
Topics: Histamine H1 Antagonists; Histamine Release; Humans; Hydroxyurea; Indazoles; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Lung; Lung Neoplasms; Pyrilamine; Quinolines | 1999 |
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Choriocarcinoma; Dinoprost; Dinoprostone; Enzyme Inhibitors; Humans; Hydroxysteroid Dehydrogenases; Hydroxyurea; Indomethacin; Isoenzymes; Leukotriene B4; Lipoxygenase Inhibitors; Masoprocol; Placenta; Prostaglandins; Tumor Cells, Cultured | 1999 |
Leukotriene modifiers--a new treatment option for asthma.
Topics: Acetates; Anti-Asthmatic Agents; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Phenylcarbamates; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds; Treatment Outcome | 1999 |
Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells.
Topics: Animals; Antigens; Arachidonic Acid; Calcimycin; Cell Degranulation; Cell Line; Chromans; Culture Media, Conditioned; Hydroxyurea; Hypoglycemic Agents; Immunoglobulin E; Leukotriene B4; Leukotriene C4; Leukotriene E4; Leukotrienes; Lipoxygenase Inhibitors; Male; Mast Cells; Neutrophils; Prostaglandin D2; Rats; Rats, Sprague-Dawley; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Drugs for asthma.
Topics: Acetates; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adult; Albuterol; Asthma; Bronchial Spasm; Child; Cromolyn Sodium; Cyclopropanes; Exercise; Female; Growth Disorders; Humans; Hydroxyurea; Indoles; Ipratropium; Lactation; Leukotriene Antagonists; Nebulizers and Vaporizers; Nedocromil; Phenylcarbamates; Pregnancy; Pregnancy Complications; Quinolines; Salmeterol Xinafoate; Sulfides; Sulfonamides; Theophylline; Tosyl Compounds | 2000 |
5-Lipoxygenase inhibition: a new treatment strategy for Sjögren-Larsson syndrome.
Topics: Aldehyde Oxidoreductases; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Sjogren-Larsson Syndrome | 2000 |
The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI).
Topics: Abnormalities, Drug-Induced; Acetates; Administration, Inhalation; Administration, Intranasal; Administration, Oral; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Animals; Anti-Allergic Agents; Anti-Asthmatic Agents; Asthma; Budesonide; Chlorpheniramine; Cyclopropanes; Ephedrine; Female; Histamine H1 Antagonists; Humans; Hydroxyurea; Hypersensitivity; Indoles; Ipratropium; Leukotriene Antagonists; Metaproterenol; Nasal Decongestants; Nebulizers and Vaporizers; Nedocromil; Phenylcarbamates; Pregnancy; Pregnancy Complications; Quinolines; Salmeterol Xinafoate; Sulfides; Sulfonamides; Terbutaline; Tosyl Compounds; Tripelennamine | 2000 |
Recurrent panniculitis in a man with asthma receiving treatment with leukotriene-modifying agents.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Cyclopropanes; Diagnosis, Differential; Erythema Induratum; Humans; Hydroxyurea; Leukotriene Antagonists; Lipoxygenase Inhibitors; Male; Middle Aged; Panniculitis, Nodular Nonsuppurative; Quinolines; Sulfides | 2000 |
Antileukotriene agents and aspirin-sensitive asthma: are we removing the second bassoonist or skating to where the puck is gonna be?
Topics: Aspirin; Asthma; Bronchial Spasm; Humans; Hydroxyurea; Leukotriene Antagonists; Therapeutic Equivalency | 2000 |
Lack of effect of the 5-lipoxygenase inhibitor zileuton in blocking oral aspirin challenges in aspirin-sensitive asthmatics.
Topics: Administration, Oral; Aspirin; Asthma; Desensitization, Immunologic; Humans; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors | 2000 |
Nasal secretion in ragweed-sensitized dogs: effect of leukotriene synthesis inhibition.
Topics: Animals; Dogs; Hydroxyurea; Hypersensitivity; Leukotriene Antagonists; Leukotriene B4; Nasal Mucosa; Nasal Obstruction; Nasal Provocation Tests; Neutrophils; Plants; Pollen; Rhinitis, Allergic, Seasonal; Time Factors | 2000 |
Modulation of alveolar macrophage phagocytosis by leukotrienes is Fc receptor-mediated and protein kinase C-dependent.
Topics: Acetophenones; Animals; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythrocytes; Female; Hydroxyurea; Immune Sera; Immunoglobulin G; Klebsiella pneumoniae; Leukotriene Antagonists; Leukotrienes; Macrophages, Alveolar; Microspheres; Naphthalenes; Phagocytosis; Protein Kinase C; Rats; Rats, Wistar; Receptors, Cell Surface; Receptors, Fc; Receptors, Leukotriene B4; Sheep; Staurosporine; Tetradecanoylphorbol Acetate; Tetrazoles | 2000 |
N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase.
Topics: Antioxidants; Arachidonate 5-Lipoxygenase; Hydroxyurea; Indoles; Lipoxygenase Inhibitors; Pyrazoles | 2001 |
Clinical predictors of health-related quality of life depend on asthma severity.
Topics: Adult; Albuterol; Analysis of Variance; Asthma; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Predictive Value of Tests; Probability; Quality of Life; Respiratory Function Tests; Retrospective Studies; Severity of Illness Index; Sickness Impact Profile; Treatment Outcome | 2001 |
Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Asteraceae; Calcium; Complement C5a; Cysteine; Eosinophils; Humans; Hydroxyurea; In Vitro Techniques; Leukotriene B4; Leukotrienes; Macrophages; Neutrophils; Plant Extracts; Platelet Activating Factor; Sesquiterpenes; Signal Transduction | 2001 |
Safety of antileukotriene agents in asthma management.
Topics: Acetates; Asthma; Churg-Strauss Syndrome; Clinical Trials as Topic; Cyclopropanes; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Phenylcarbamates; Quinolines; Sulfides; Sulfonamides; Tosyl Compounds | 2001 |
In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
Topics: Animals; Arachidonate 5-Lipoxygenase; Benzothiazoles; Dinoprostone; Dose-Response Relationship, Drug; Eicosanoids; Humans; Hydroxyurea; Indomethacin; Leukocytes; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mesalamine; Methacrylates; Neutrophils; Peritoneal Cavity; Prostaglandin-Endoperoxide Synthases; Pyridines; Rats; Rats, Inbred F344; Sheep; Sulfasalazine; Thiazoles; Thromboxane B2; Thromboxane-A Synthase | 2001 |
Modulation of haem oxygenase-1 expression by nitric oxide and leukotrienes in zymosan-activated macrophages.
Topics: Amidines; Animals; Benzylamines; Cell Line; Chick Embryo; Cyclooxygenase 2; Dexamethasone; Dinoprostone; Dose-Response Relationship, Drug; Eicosanoids; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Hydroxyurea; Indomethacin; Isoenzymes; Leukotriene B4; Leukotriene C4; Leukotrienes; Macrophage Activation; Macrophages; NF-kappa B; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitrites; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Protein Binding; Pyrans; Quinolones; Sulfonamides; Time Factors; Transcription Factor AP-1; Zymosan | 2001 |
Induction of hepatic microsomal drug-metabolizing enzymes by inhibitors of 5-lipoxygenase (5-LO): studies in rats and 5-LO knockout mice.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Hydroxyurea; Lipoxygenase Inhibitors; Liver; Male; Mice; Mice, Inbred DBA; Mice, Knockout; Microsomes, Liver; NADH Dehydrogenase; Organ Size; Pyrans; Quinolones; Rats; Rats, Sprague-Dawley | 2001 |
Zileuton and atopic dermatitis.
Topics: Dermatitis, Atopic; Humans; Hydroxyurea; Immunoglobulin E; T-Lymphocytes; Treatment Outcome | 2001 |
Peroxynitrite-induced nitrotyrosination of proteins is blocked by direct 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Blotting, Western; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Nitrates; omega-N-Methylarginine; Precipitin Tests; Proteins; Rats; Rats, Wistar; Tyrosine | 2001 |
Leukotrienes play protective roles early during experimental VSV encephalitis.
Topics: Animals; Arachidonate 5-Lipoxygenase; Blood-Brain Barrier; Brain; CD4-Positive T-Lymphocytes; CHO Cells; Cricetinae; Encephalitis, Viral; Hydroxyurea; Immunohistochemistry; Interferon-gamma; Interleukin-12; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Neutrophil Activation; Nitric Oxide; Nitric Oxide Synthase; Vesicular stomatitis Indiana virus; Viral Load | 2001 |
Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome.
Topics: Adolescent; Adult; Brain; Electroencephalography; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Neuropsychological Tests; Sjogren-Larsson Syndrome | 2001 |
Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase II: in vivo studies.
Topics: Administration, Oral; Administration, Topical; Animals; Arthus Reaction; beta-Alanine; Dermatitis; Edema; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Hydroxyurea; In Vitro Techniques; Leukotriene A4; Leukotriene Antagonists; Lipoxygenase Inhibitors; Mice; Peritoneum; Rats; Skin | 2002 |
Treatment of disseminated granuloma annulare with a 5-lipoxygenase inhibitor and vitamin E.
Topics: Drug Therapy, Combination; Female; Follow-Up Studies; Granuloma Annulare; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Middle Aged; Vitamin E | 2002 |
Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes.
Topics: Adult; Cell Count; Exercise; Female; Histamine H1 Antagonists; Humans; Hydroxyurea; Hypoxia; Inflammation Mediators; Leukotriene Antagonists; Leukotriene E4; Lung; Male; Oxygen Consumption; Pulmonary Gas Exchange; Respiratory Function Tests; Sports; Sputum; Terfenadine | 2002 |
Effects of Celebrex and Zyflo on BOP-induced pancreatic cancer in Syrian hamsters.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Celecoxib; Cricetinae; Glutathione; Hydroxyurea; Incidence; Lipoxygenase Inhibitors; Male; Mesocricetus; Pancreas; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice.
Topics: Animals; Anticarcinogenic Agents; Carcinogens; Dose-Response Relationship, Drug; Female; Hydroxyurea; Indoles; Leukotriene Antagonists; Lipoxygenase Inhibitors; Lung Neoplasms; Mice; Mice, Inbred A; Phenylcarbamates; Sulfonamides; Tosyl Compounds; Urethane | 2002 |
Interaction between nitric oxide, reactive oxygen intermediates, and peroxynitrite in the regulation of 5-lipoxygenase metabolism.
Topics: Animals; Arachidonate 5-Lipoxygenase; Down-Regulation; Female; Free Radical Scavengers; Hydrogen Peroxide; Hydroxyurea; Leukotrienes; Lipopolysaccharides; Lipoxygenase Inhibitors; Macrophages, Alveolar; Nitric Oxide; Peroxynitrous Acid; Rats; Rats, Wistar; Reactive Oxygen Species; Xanthine Oxidase | 2002 |
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cricetinae; Hydroxyurea; Lipid Peroxidation; Lipoxygenase Inhibitors; Liver Neoplasms; Male; Mesocricetus; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2002 |
Anti-leukotriene drugs in the prevention and treatment of hepatorenal syndrome.
Topics: Acetates; Arachidonic Acid; Cyclopropanes; Hepatorenal Syndrome; Humans; Hydroxyurea; Indoles; Leukotriene Antagonists; Leukotrienes; Liver; Phenylcarbamates; Protein Structure, Tertiary; Quinolines; Sulfides; Sulfonamides; Thromboxanes; Tosyl Compounds | 2003 |
Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Blood Glucose; Blood Urea Nitrogen; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diuresis; Hydroxyurea; Lipoxygenase Inhibitors; Male; Membrane Proteins; Proteinuria; Quinolines; Rats; Rats, Sprague-Dawley | 2002 |
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.
Topics: Animals; Bothrops; Bradykinin; Carrageenan; Celecoxib; Crotalid Venoms; Heparin; Hindlimb; Histamine Antagonists; Hydroxyurea; Hyperalgesia; Male; omega-N-Methylarginine; Peptides; Phospholipases A; Pyrazoles; Rats; Rats, Wistar; Serotonin Antagonists; Sulfonamides; Time Factors | 2003 |
Zileuton reduces respiratory illness and lung inflammation, during respiratory syncytial virus infection, in mice.
Topics: Animals; Bronchoalveolar Lavage Fluid; Cell Count; Disease Models, Animal; Hydroxyurea; Inflammation; Leukotriene Antagonists; Leukotrienes; Lung; Mice; Mice, Inbred BALB C; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Time Factors; Virus Replication; Weight Loss | 2003 |
A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor.
Topics: Acne Vulgaris; Administration, Oral; Adolescent; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Pilot Projects | 2003 |
Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: up-regulated TNF-alpha increases antigen driven lymphocyte proliferation.
Topics: Adenine; Adenylyl Cyclases; Anti-HIV Agents; Cell Division; Cyclooxygenase Inhibitors; Humans; Hydroxyurea; Immunotherapy; Lipoxygenase Inhibitors; Lymphocytes; Neoplasms; Organophosphonates; Organophosphorus Compounds; Tenofovir; Tumor Necrosis Factor-alpha; Up-Regulation | 2003 |
Zileuton, a 5-lipoxygenase inhibitor, increases production of thromboxane A2 and platelet aggregation in patients with asthma.
Topics: Adult; Aged; Asthma; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Middle Aged; Platelet Aggregation; Thromboxane A2; Thromboxane B2 | 2003 |
Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
Topics: Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Microsomes, Liver | 2003 |
Generalized granuloma annulare in a patient with adult onset diabetes mellitus.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arm; Diabetes Mellitus, Type 2; Diagnosis, Differential; Granuloma Annulare; Hand; Humans; Hydroxyurea; Male; Vitamin E | 2003 |
Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway.
Topics: Anemia, Sickle Cell; Arginine; Case-Control Studies; Cells, Cultured; Cyclic GMP; Dose-Response Relationship, Drug; Erythroid Precursor Cells; Fetal Hemoglobin; Gene Expression Regulation; Humans; Hydroxyurea; K562 Cells; Nitric Oxide; Nitric Oxide Synthase; Signal Transduction | 2004 |
In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity.
Topics: Animals; Cell Line; Glutathione; Half-Life; Humans; Hydroxyurea; Liver; Magnetic Resonance Spectroscopy; Rats; Spectrometry, Mass, Electrospray Ionization; Thiophenes | 2004 |
Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma?
Topics: Acetates; Adult; Anti-Asthmatic Agents; Asthma; Cyclopropanes; Female; Health Status Indicators; Hospitalization; Humans; Hydroxyurea; Leukotriene Antagonists; Logistic Models; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Quinolines; Sulfides | 2004 |
Effect of zileuton in radicular pain induced by herniated nucleus pulposus in rats.
Topics: Animals; Female; Hydroxyurea; Intervertebral Disc Displacement; Pain; Pain Measurement; Rats; Rats, Wistar | 2004 |
Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Inflammation; Intercellular Adhesion Molecule-1; Ischemia; Kidney Diseases; Leukotriene B4; Lipoxygenase Inhibitors; Mice; Mice, Knockout; Neutrophils; Peroxidase; Reperfusion Injury | 2004 |
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone.
Topics: Acetylcholine; Animals; Aorta; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelium, Vascular; Hydroxyurea; Lipoxins; Lipoxygenase Inhibitors; Male; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroarginine; Oligopeptides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Lipoxin; Sulfonamides; Vascular Resistance; Vasodilation; Vasodilator Agents | 2004 |
Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Arachidonate 5-Lipoxygenase; CD11 Antigens; CD18 Antigens; Chemotaxis, Leukocyte; Disease Models, Animal; Endotoxemia; Enzymes; Gene Targeting; Hydroxyurea; Leukocytes; Lipopolysaccharides; Lipoxygenase Inhibitors; Liver; Lung; Male; Mice; Mice, Knockout; Multiple Organ Failure; Pancreas; Rats; Rats, Wistar; Viscera | 2004 |
The improved survival of experimental animals fed with fish oil is suppressed by a leukotriene inhibitor.
Topics: Animals; Dietary Fats, Unsaturated; Female; Fish Oils; Hydroxyurea; Klebsiella Infections; Klebsiella pneumoniae; Leukotriene Antagonists; Leukotrienes; Lipoxygenase Inhibitors; Mice | 2004 |
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 5-Lipoxygenase; Body Weight; Celecoxib; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Esophageal Neoplasms; Humans; Hydroxyurea; Immunohistochemistry; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors | 2004 |
Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production.
Topics: Administration, Oral; Adult; Dermatitis, Seborrheic; Drug Administration Schedule; Face; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Neck; Scalp; Sebaceous Gland Diseases; Sebum | 2005 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogens; Carcinoma, Squamous Cell; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Cricetinae; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Hydroxyurea; Immunohistochemistry; In Situ Hybridization; Lipoxygenase Inhibitors; Male; Membrane Proteins; Mesocricetus; Mouth Neoplasms; Neoplasms, Experimental; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Up-Regulation | 2005 |
Differential effects of hydroxyurea and zileuton on interleukin-13 secretion by activated murine spleen cells: implication on the expression of vascular cell adhesion molecule-1 and vasoocclusion in sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Female; Hydroxyurea; Interleukin-13; Lymphocytes; Mice; Mice, Inbred C57BL; Spleen; Vascular Cell Adhesion Molecule-1; Vasoconstriction | 2005 |
Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats.
Topics: Acetates; Acetic Acid; Analgesics; Animals; Capillary Permeability; Carrageenan; Cyclopropanes; Dose-Response Relationship, Drug; Female; Hindlimb; Hydroxyurea; Hyperalgesia; Indoles; Inflammation; Leukotriene Antagonists; Lipoxygenase Inhibitors; Male; Mice; Pain; Pain Measurement; Phenylcarbamates; Quinolines; Rats; Rats, Wistar; Receptors, Leukotriene B4; Sulfides; Sulfonamides; Tosyl Compounds | 2005 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoprostone; Drug Therapy, Combination; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Liver; Liver Neoplasms; Pancreas; Pancreatic Neoplasms; Prostaglandins; Prostaglandins F; Pyrazoles; Sulfonamides | 2005 |
Modification of eicosanoid profile in human blood treated by dual COX/LOX inhibitors.
Topics: Arachidonic Acid; Calcimycin; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase Inhibitors; Eicosanoids; Humans; Hydroxyurea; Indomethacin; Inhibitory Concentration 50; Lipopolysaccharides; Lipoxygenase Inhibitors; Pyrazoles; Sulfonamides | 2005 |
Effect of 5-lipoxygenase inhibitor against lipopolysaccharide-induced hypothermia in mice.
Topics: Animals; Colon; Dinoprostone; Female; Hydroxyurea; Hypothalamus; Hypothermia; Hypothermia, Induced; Indomethacin; Leukotriene B4; Leukotrienes; Lipopolysaccharides; Lipoxygenase Inhibitors; Male; Mice | 2005 |
Differential regulation by leukotrienes and calcium of Fc gamma receptor-induced phagocytosis and Syk activation in dendritic cells versus macrophages.
Topics: Animals; Antigen Presentation; Bone Marrow Cells; Calcium Signaling; Cells, Cultured; Dendritic Cells; Endocytosis; Enzyme Activation; Erythrocytes; Hydroxyurea; Immunoglobulin G; Indoles; Intracellular Signaling Peptides and Proteins; Leukotriene B4; Macrophages; Macrophages, Alveolar; Macrophages, Peritoneal; Mice; Mice, Inbred CBA; Mice, Knockout; Opsonin Proteins; Phagocytosis; Phosphorylation; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Purinergic P2 Receptor Antagonists; Rats; Rats, Wistar; Receptors, IgG; Receptors, Leukotriene B4; Sheep; Syk Kinase | 2006 |
Activated neutrophil-mediated sickle red blood cell adhesion to lung vascular endothelium: role of phosphatidylserine-exposed sickle red blood cells.
Topics: Anemia, Sickle Cell; Animals; Annexin A5; Arachidonate 5-Lipoxygenase; Cell Adhesion; Endothelium, Vascular; Enzyme Inhibitors; Erythrocytes, Abnormal; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Male; Neutrophil Activation; Neutrophils; Phosphatidylserines; Rats; Rats, Sprague-Dawley | 2006 |
Quantum chemical design of hydroxyurea derivatives for the treatment of sickle-cell anemia.
Topics: Anemia, Sickle Cell; Antisickling Agents; Free Radicals; Humans; Hydroxyurea; Nitric Oxide Donors; Quantum Theory | 2005 |
Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
Topics: Adenoma; Administration, Inhalation; Administration, Oral; Animals; Benzo(a)pyrene; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Hydroxamic Acids; Hydroxyurea; Incidence; Lipoxygenase Inhibitors; Lung Neoplasms; Mice; Mice, Inbred Strains; Phenylurea Compounds | 2007 |
Effects of ertiprotafib on hepatic cytochrome P450 and peroxisomal enzymes in rats and dogs, and in rat and human primary hepatocytes.
Topics: Animals; Cytochrome P-450 Enzyme System; Dogs; Enzyme Induction; Female; Glucuronosyltransferase; Hepatocytes; Humans; Hydroxyurea; Hypoglycemic Agents; Liver; Male; Microsomes, Liver; Organ Size; Peroxisomes; Phenylpropionates; Rats; RNA, Messenger; Thiazolidinediones; Thiophenes; Thyroid Gland | 2007 |
Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Ascitic Fluid; Benzothiazoles; Dogs; Ear; Edema; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Female; Humans; Hydroxyurea; Inflammation; Leukotriene B4; Leukotriene C4; Lipoxins; Lipoxygenase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Neutrophil Infiltration; Peritonitis; Piperidines; Recombinant Proteins | 2007 |
Effects of leukotriene inhibition on pulmonary morphology in rat pup lungs exposed to hyperoxia.
Topics: Animals; Animals, Newborn; Female; Hydroxyurea; Hyperoxia; Indoles; Leukotriene Antagonists; Lung; Lung Diseases; Male; Oxygen; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Sulfonamides; Tosyl Compounds | 2007 |
Possible involvement of 5-lipoxygenase metabolite in itch-associated response of mosquito allergy in mice.
Topics: Animals; Arachidonate 5-Lipoxygenase; Betamethasone Valerate; Bridged Bicyclo Compounds, Heterocyclic; Calcium; Chromones; Cimetidine; Culicidae; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hydrazines; Hydroxyurea; Hypersensitivity; Indoles; Indomethacin; Ketoprofen; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred ICR; NG-Nitroarginine Methyl Ester; Phenylpropionates; Phospholipid Ethers; Propionates; Pruritus; Quinolines; Terfenadine | 2007 |
Irreversible alkylation of human serum albumin by zileuton metabolite 2-acetylbenzothiophene-S-oxide: a potential model for hepatotoxicity.
Topics: Alkylation; Anti-Asthmatic Agents; Binding, Competitive; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Half-Life; Humans; Hydroxyurea; Ibuprofen; Models, Biological; Serum Albumin; Tandem Mass Spectrometry; Thiophenes; Warfarin | 2007 |
Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Topics: Acetates; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Cyclopropanes; Cysteine; Dinoprostone; Disease Models, Animal; Gene Expression Regulation; Hydroxyurea; Inflammation; Leukotrienes; Lipoxygenase Inhibitors; Male; Mice; Neutrophil Infiltration; Quinolines; Recovery of Function; Spinal Cord Injuries; Sulfides; Tumor Necrosis Factor-alpha | 2008 |
Reactions of in situ generated N-Boc nitrones with aromatic and heteroaromatic grignard reagents: application to the synthesis of zileuton.
Topics: Hydroxyurea; Indicators and Reagents; Nitrogen Oxides | 2008 |
Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Eicosanoids; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lung Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Up-Regulation | 2008 |
A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
Topics: Air; Animals; Arachidonate 5-Lipoxygenase; Biological Assay; Calcimycin; Carrageenan; Cell Line, Tumor; Chromatography, Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyurea; Imidazoles; Immunoglobulin E; Inflammation; Ionophores; Leukotrienes; Lipoxygenase Inhibitors; Male; Mast Cells; Oxidation-Reduction; Rats; Rats, Inbred Lew; Reproducibility of Results; Sulfides; Tandem Mass Spectrometry | 2008 |
Pharmacological intervention to the inflammatory response from decompression sickness in rats.
Topics: Animals; Cyclooxygenase Inhibitors; Decompression Sickness; Hydroxyurea; Indoles; Indomethacin; Inflammation; Isoproterenol; Lipoxygenase Inhibitors; Lysine; Male; Phenylcarbamates; Pulmonary Edema; Rats; Rats, Sprague-Dawley; Sulfonamides; Tosyl Compounds | 2008 |
Crotoxin alters lymphocyte distribution in rats: Involvement of adhesion molecules and lipoxygenase-derived mediators.
Topics: Animals; Cell Adhesion; Cell Adhesion Molecules; Crotoxin; Eicosanoids; Endothelial Cells; Hydroxyurea; Lipoxygenase; Lipoxygenase Inhibitors; Lymph; Lymph Nodes; Lymphatic Vessels; Lymphocyte Count; Lymphocytes; Male; Phospholipases A2; Rats; Rats, Wistar; Spleen; Thoracic Duct | 2008 |
Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Topics: Apoptosis; Cell Line, Tumor; Fibroblast Growth Factor 2; Golgi Apparatus; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Masoprocol; Multiple Myeloma; Phosphorylation; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Thanatophoric Dysplasia; Transfection | 2008 |
Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses.
Topics: Analysis of Variance; Animals; Benzoates; Cell Proliferation; Cells, Cultured; Cyclooxygenase Inhibitors; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Female; Glycoproteins; Group IV Phospholipases A2; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Myelin-Oligodendrocyte Glycoprotein; Naproxen; Peptide Fragments; Severity of Illness Index; Seveso Accidental Release; Sulfonamides; Th1 Cells; Time Factors | 2008 |
Oxygen-glucose deprivation activates 5-lipoxygenase mediated by oxidative stress through the p38 mitogen-activated protein kinase pathway in PC12 cells.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Antioxidants; Antipyrine; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carrier Proteins; Cell Hypoxia; Edaravone; Enzyme Activation; Enzyme Inhibitors; Glucose; Hydrogen Peroxide; Hydroxyurea; Imidazoles; Indoles; Leukotrienes; Lipoxygenase Inhibitors; MAP Kinase Signaling System; Membrane Proteins; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; PC12 Cells; Phosphorylation; Pyridines; Rats; Reactive Oxygen Species; Transfection | 2009 |
Leukotriene pathways and in vitro adenotonsillar cell proliferation in children with obstructive sleep apnea.
Topics: Acetates; Adenoids; Apoptosis; Cell Proliferation; Cells, Cultured; Child; Child, Preschool; Cyclopropanes; Dose-Response Relationship, Drug; Humans; Hydroxyurea; Immunohistochemistry; Interleukins; Leukotriene Antagonists; Leukotriene D4; Palatine Tonsil; Polysomnography; Quinolines; Sleep Apnea, Obstructive; SRS-A; Sulfides | 2009 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Combinations; Head and Neck Neoplasms; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, Nude; Pyrazoles; Random Allocation; Skin Neoplasms; Sulfonamides | 2009 |
2-ABT-S-oxide detoxification by glutathione S-transferases A1-1, M1-1 and P1-1: implications for toxicity associated with zileuton.
Topics: Chromatography, Liquid; Glutathione Transferase; Hydroxyurea; Inactivation, Metabolic; Isoenzymes; Kinetics; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Thiophenes; Toxicity Tests | 2009 |
5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9.
Topics: Animals; Arachidonate 5-Lipoxygenase; Body Water; Brain; Brain Edema; Brain Ischemia; Dose-Response Relationship, Drug; Down-Regulation; Hydroxyurea; Infarction, Middle Cerebral Artery; Lipoxygenase Inhibitors; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions.
Topics: Allergens; Anaphylaxis; Animals; Arachis; Cholera Toxin; Cimetidine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histamine; Histamine Antagonists; Histamine H1 Antagonists; Hydroxyurea; Immunoglobulin E; Immunoglobulin G; Lipoxygenase Inhibitors; Mice; Mice, Inbred C57BL; Peanut Hypersensitivity; Platelet Membrane Glycoproteins; Pyrilamine; Receptors, G-Protein-Coupled; Receptors, Histamine | 2009 |
Enhanced fracture repair by leukotriene antagonism is characterized by increased chondrocyte proliferation and early bone formation: a novel role of the cysteinyl LT-1 receptor.
Topics: Acetates; Animals; Arachidonate 5-Lipoxygenase; Cell Proliferation; Chondrocytes; Cyclopropanes; Fracture Healing; Fractures, Bone; Gene Expression Regulation; Hydroxyurea; Hypertrophy; Leukotriene Antagonists; Leukotriene B4; Mice; Models, Biological; Osteogenesis; Quinolines; Radiography; Receptors, Leukotriene; Sulfides | 2009 |
CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.
Topics: Administration, Oral; Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Cell Line; Disease Models, Animal; Enzyme Inhibitors; Freund's Adjuvant; Humans; Hydroxyurea; Imidazoles; Immunohistochemistry; Inflammation; Leukotrienes; Lipoxygenase Inhibitors; Male; Osteoarthritis; Pain; Rats; Rats, Sprague-Dawley; Substrate Specificity; Sulfides | 2009 |
Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis.
Topics: Arachidonic Acid; Cell Count; Cell Line; Humans; Hydroxyurea; Interleukin-6; Interleukin-8; Leukotriene Antagonists; Leukotriene B4; Lipogenesis; Sebaceous Glands | 2010 |
Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation.
Topics: Cyclic GMP; Erythroid Cells; Fetal Hemoglobin; gamma-Globins; Humans; Hydrogen Peroxide; Hydroxyurea; K562 Cells; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitrites; omega-N-Methylarginine; Signal Transduction; Stem Cells; Transcription, Genetic; Transcriptional Activation | 2009 |
Induction of leukotriene B(4) and prostaglandin E(2) release from keratinocytes by protease-activated receptor-2-activating peptide in ICR mice.
Topics: Animals; Cetirizine; Dinoprostone; Dose-Response Relationship, Drug; Drug Interactions; Hydroxyurea; Indomethacin; Injections, Intradermal; Keratinocytes; Leukotriene B4; Male; Mice; Mice, Inbred ICR; Oligopeptides; Pruritus; Skin; Tacrolimus | 2009 |
The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cytoprotection; Dinoprostone; Enzyme Activation; Hydrogen Peroxide; Hydroxyurea; Lipoxygenase Inhibitors; MAP Kinase Signaling System; Myocytes, Cardiac; Protein Kinase C-delta; Rats | 2010 |
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Benzamides; Carrier Proteins; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipoxygenase Inhibitors; Membrane Proteins; Mice; Mice, Knockout; Myeloproliferative Disorders; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Targeting Ca2+ release-activated Ca2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis.
Topics: Acetates; Arachidonate 5-Lipoxygenase; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Signaling; Cyclopropanes; Humans; Hydroxyurea; Leukotriene Antagonists; Leukotriene C4; Mast Cells; Nasal Polyps; Quinolines; Receptors, Leukotriene; Sulfides; Thapsigargin | 2009 |
Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors.
Topics: Animals; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Gene Expression; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mouth Neoplasms; Naproxen; Piroxicam; Pyrazoles; Rats; Rats, Inbred F344; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Up-Regulation | 2010 |
Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model.
Topics: Adenoma; Administration, Inhalation; Animals; Benzo(a)pyrene; Chemistry, Pharmaceutical; Dosage Forms; Ethanol; Female; Hydroxyurea; Inhalation; Lung; Lung Neoplasms; Mice; Mice, Inbred A | 2010 |
Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Brain; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Encephalitis; Enzyme-Linked Immunosorbent Assay; Hydroxyurea; Immunohistochemistry; Interleukin-1beta; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Malondialdehyde; Neuroprotective Agents; Neutrophil Infiltration; Nitric Oxide; Nitric Oxide Synthase Type II; Peroxidase; Rats; Rats, Sprague-Dawley; Time Factors; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2010 |
Multitarget drugs: synthesis and preliminary pharmacological characterization of zileuton analogues endowed with Dual 5-LO inhibitor and NO-dependent activities.
Topics: Animals; Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Drug Design; Edema; Hydroxyurea; Leukotriene B4; Lipoxygenase Inhibitors; Nitric Oxide; Rats; Structure-Activity Relationship | 2010 |
The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
Topics: Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carrageenan; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Humans; Hydroxyurea; Interferon-gamma; Intramolecular Oxidoreductases; Lipopolysaccharides; Lipoxygenase Inhibitors; Macrophages; Mice; Mice, Inbred Strains; Pleurisy; Prostaglandin-E Synthases; Prostaglandins F; Rats; Rats, Wistar; Zymosan | 2010 |
Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Female; Fibroblasts; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Mice; Mice, Transgenic; Models, Biological; Mutation; Phenotype; Receptors, Notch | 2011 |
[5-lipoxygenase is involved in rotenone-induced injury in PC12 cells].
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Survival; Hydroxyurea; Lipoxygenase Inhibitors; PC12 Cells; Rats; Rotenone | 2011 |
Involvement of leukotriene B4 in itching in a mouse model of ocular allergy.
Topics: Allergens; Ambrosia; Animals; Conjunctivitis, Allergic; Disease Models, Animal; Glucocorticoids; Histamine; Histamine H1 Antagonists, Non-Sedating; Hydroxyurea; Immunoglobulin E; Immunoglobulin G; Immunosuppressive Agents; Injections, Intraocular; Injections, Subcutaneous; Leukotriene B4; Lipoxygenase Inhibitors; Male; Mast Cells; Mice; Mice, Inbred ICR; Phenylpropionates; Pollen; Terfenadine | 2012 |
Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice.
Topics: Adipocytes; Adipose Tissue; Animals; Arachidonate 5-Lipoxygenase; Cell Line; Chemokines; Cytokines; Diet, High-Fat; Female; Humans; Hydroxyurea; Inflammation; Insulin Resistance; Leukotrienes; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Obesity; Subcutaneous Fat | 2012 |
Nuclear translocation of cysteinyl leukotriene receptor 1 is involved in oxygen-glucose deprivation-induced damage to endothelial cells.
Topics: Apoptosis; Brain Ischemia; Cell Culture Techniques; Cell Hypoxia; Cell Line; Cell Membrane; Cell Nucleus; Cell Survival; Chromones; Endothelial Cells; Glucose; Humans; Hydroxyurea; Ligands; Models, Biological; Nuclear Localization Signals; Oxygen; Protein Transport; Receptors, Leukotriene | 2012 |
Effects of montelukast and zileuton on testicular torsion/detorsion injury in rats.
Topics: Acetates; Animals; Cyclopropanes; Hydroxyurea; Male; Malondialdehyde; Quinolines; Rats; Rats, Wistar; Spermatic Cord Torsion; Sulfides | 2014 |
Inhibitory effect of Crotalus durissus terrificus venom on chronic edema induced by injection of bacillus Calmette-Guérin into the footpad of mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; BCG Vaccine; Chronic Disease; Crotalid Venoms; Crotalus; Crotoxin; Dexamethasone; Edema; Foot; Hindlimb; Hydroxyurea; Inflammation; Injections, Subcutaneous; Lipoxygenase; Male; Mice; Mycobacterium bovis | 2013 |
5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Cyclin-Dependent Kinase 5; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, Transgenic; Phosphorylation; Random Allocation; tau Proteins | 2013 |
Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Arachidonate 5-Lipoxygenase; Brain; Conditioning, Classical; Disease Models, Animal; Excitatory Postsynaptic Potentials; Fear; Gene Expression Regulation; Humans; Hydroxyurea; In Vitro Techniques; Lipoxygenase Inhibitors; Memory Disorders; Mice; Mice, Transgenic; Mutation; Presenilin-1; Synapses; tau Proteins | 2014 |
[Expression of 5-lipoxygenase in hippocampal CA1 neuronal damage following global cerebral ischemia in rats].
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain Ischemia; CA1 Region, Hippocampal; Disease Models, Animal; Hydroxyurea; Lipoxygenase Inhibitors; Male; Neurons; Rats; Rats, Sprague-Dawley | 2013 |
Deoxyhypusine hydroxylase from Plasmodium vivax, the neglected human malaria parasite: molecular cloning, expression and specific inhibition by the 5-LOX inhibitor zileuton.
Topics: Amino Acid Sequence; Animals; Arachidonate 5-Lipoxygenase; Cloning, Molecular; Cluster Analysis; Enzyme Activation; Gene Expression; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Malaria, Vivax; Mixed Function Oxygenases; Molecular Sequence Data; Phycocyanin; Plasmodium vivax; Sequence Alignment; Transcription, Genetic | 2013 |
NMR metabolomics analysis of the effects of 5-lipoxygenase inhibitors on metabolism in glioblastomas.
Topics: Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Caffeic Acids; Cell Line, Tumor; Drug Screening Assays, Antitumor; Free Radical Scavengers; Glioblastoma; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxyurea; Leukotrienes; Lipid Metabolism; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Metabolome; Metabolomics; Phenylethyl Alcohol; Principal Component Analysis | 2013 |
5-Lipoxygenase inhibitor zileuton inhibits neuronal apoptosis following focal cerebral ischemia.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Brain; Brain Injuries; Caspase 1; Caspase 3; Hydroxyurea; Infarction, Middle Cerebral Artery; Lipoxygenase Inhibitors; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley | 2013 |
Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Arachidonate 5-Lipoxygenase; Cognition; Cyclin-Dependent Kinase 5; Female; Humans; Hydroxyurea; Immunoblotting; Immunohistochemistry; Lipoxygenase Inhibitors; Male; Maze Learning; Memory Disorders; Mice; Mice, Transgenic; Neurofibrillary Tangles; Phosphorylation; Plaque, Amyloid; Synapses; tau Proteins | 2013 |
Airway remodeling in asthma: tumor of the airway?
Topics: Airway Remodeling; Allergens; Animals; Asthma; Hydroxyurea; Leukotriene Antagonists; Lung; Male | 2013 |
Effects of zileuton on airway smooth muscle remodeling after repeated allergen challenge in brown Norway rats.
Topics: Airway Remodeling; Allergens; Animals; Asthma; Bronchoalveolar Lavage Fluid; Drug Evaluation, Preclinical; Hydroxyurea; Leukotriene Antagonists; Lung; Male; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Rats; Respiratory Function Tests; T-Lymphocytes | 2013 |
Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydroxyurea; Linear Models; Lipoxygenase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Inhibitor of 5-lipoxygenase, zileuton, suppresses prostate cancer metastasis by upregulating E-cadherin and paxillin.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cadherins; Cell Migration Assays; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Paxillin; Prostatic Neoplasms; Up-Regulation | 2013 |
Increased metabolites of 5-lipoxygenase from hypoxic ovarian cancer cells promote tumor-associated macrophage infiltration.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Line; Cell Line, Tumor; Chemotaxis, Leukocyte; Disease Models, Animal; Female; Heparin-binding EGF-like Growth Factor; Heterografts; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukotriene B4; Macrophages; MAP Kinase Signaling System; Matrix Metalloproteinase 7; Mice; Neoplasm Metastasis; Ovarian Neoplasms; Tumor Necrosis Factor-alpha | 2015 |
Chronic hypoxia promotes pulmonary artery endothelial cell proliferation through H2O2-induced 5-lipoxygenase.
Topics: Arachidonate 5-Lipoxygenase; Cell Hypoxia; Cell Line; Cell Proliferation; Endothelial Cells; Humans; Hydrogen Peroxide; Hydroxyurea; Indoles; Lipoxygenase Inhibitors; Oxygen; Pulmonary Artery | 2014 |
Involvement of leukotriene B4 in dermatophyte-related itch in mice.
Topics: Animals; Antibodies, Monoclonal; Arthrodermataceae; Dermatomycoses; Hydroxyurea; Keratinocytes; Leukotriene Antagonists; Leukotriene B4; Male; Mice, Inbred Strains; Oligopeptides; Pruritus; Receptor, PAR-2 | 2014 |
Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Amyloidogenic Proteins; Animals; Arachidonate 5-Lipoxygenase; Cyclin-Dependent Kinase 5; Hydroxyurea; Lipoxygenase Inhibitors; Memory; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Aggregates; Protein Aggregation, Pathological; tau Proteins; Up-Regulation | 2014 |
[Zileuton, a 5-lipoxygenase inhibitor, attenuates mouse microglial cell-mediated rotenone toxicity in PC12 cells].
Topics: Animals; Cell Death; Cells, Cultured; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Microglia; PC12 Cells; Rats; Rotenone | 2014 |
Antinociceptive properties of esculetin in non-inflammatory and inflammatory models of pain in rats.
Topics: Analgesia; Analgesics; Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Hyperalgesia; Inflammation; Leukotriene B4; Lipoxygenase Inhibitors; Male; Pain; Pain Threshold; Rats; Umbelliferones | 2015 |
Inhibition of 5-lipoxygenase triggers apoptosis in pancreatic cancer cells.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms | 2015 |
Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Topics: Animals; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Hydroxyurea; Inflammatory Bowel Diseases; Intestinal Polyposis; Lipoxygenase Inhibitors; Male; Mice; Mice, Mutant Strains | 2015 |
Pharmacologic inhibition of 5-lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Cerebellum; Cerebral Cortex; Cyclin-Dependent Kinase 5; Disease Models, Animal; Encephalitis; Excitatory Postsynaptic Potentials; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Memory; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Phenotype; Phosphorylation; Synapses; tau Proteins; Tauopathies | 2015 |
The 5-Lipoxygenase Inhibitor Zileuton Confers Neuroprotection against Glutamate Oxidative Damage by Inhibiting Ferroptosis.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Line; Cyclohexylamines; Glutamic Acid; Hydroxyurea; Iron; Lipoxygenase Inhibitors; Mice; Neurons; Neuroprotection; Neuroprotective Agents; Oxidative Stress; Phenylenediamines; Reactive Oxygen Species | 2015 |
The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Infarction; Carotid Stenosis; Cytokines; Disease Models, Animal; Down-Regulation; Encephalitis; Enzyme-Linked Immunosorbent Assay; Hydroxyurea; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Nervous System Diseases | 2015 |
[ROLE OF THROMBOXANE AND LEUKOTRIENES IN MECHANISMS OF CONTRACTILE REACTIONS OF PORTAL VEIN, INDUCED BY ACETYLCHLINE AND PHENYLEPHRINE].
Topics: Acetylcholine; Animals; Endothelium, Vascular; Female; Hydroxyurea; In Vitro Techniques; Leukotriene Antagonists; Leukotrienes; Male; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Phthalic Acids; Portal Vein; Rats; Receptors, Thromboxane; Thromboxanes | 2015 |
Placenta growth factor augments airway hyperresponsiveness via leukotrienes and IL-13.
Topics: Anemia, Sickle Cell; Animals; Asthma; Disease Models, Animal; Hydroxyurea; Interleukin-13; Leukotrienes; Mice; Mice, Knockout; Placenta Growth Factor; Pregnancy Proteins; Th2 Cells | 2016 |
Predictive Bioinformatic Assignment of Methyl-Bearing Stereocenters, Total Synthesis, and an Additional Molecular Target of Ajudazol B.
Topics: Arachidonate 5-Lipoxygenase; Biological Products; Computational Biology; Coumarins; Humans; Hydroxyurea; Stereoisomerism | 2016 |
5-LOX Inhibitor Zileuton Reduces Inflammatory Reaction and Ischemic Brain Damage Through the Activation of PI3K/Akt Signaling Pathway.
Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Brain Ischemia; Hydroxyurea; Infarction, Middle Cerebral Artery; Inflammation; Lipoxygenase Inhibitors; Male; Neuroprotective Agents; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats, Sprague-Dawley; Signal Transduction | 2016 |
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
Topics: Alanine; Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Azoles; Benzoquinones; Carcinogenesis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Endocannabinoids; Head and Neck Neoplasms; Humans; Hydroxyurea; Isoindoles; Lipoxygenase Inhibitors; Organoselenium Compounds; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Pyrazoles; Reactive Oxygen Species; Receptor, Cannabinoid, CB1; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TRPV Cation Channels | 2016 |
Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Body Weight; Catechin; CD3 Complex; Celecoxib; Colitis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Combinations; Eating; Gene Expression Regulation; Hydroxyurea; Leukotriene B4; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Neutrophil Infiltration; Rats; Rats, Sprague-Dawley; Thromboxane B2; Tumor Necrosis Factor-alpha | 2016 |
5-Lipoxygenase inhibitor zileuton inhibits Ca(2+)-responses induced by glutoxim and molixan in macrophages.
Topics: Animals; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Calcium; Calcium Signaling; Cations, Divalent; Cells, Cultured; Cytophotometry; Drug Combinations; Drug Interactions; Fura-2; Hydroxyurea; Inosine; Intracellular Space; Lipoxygenase Inhibitors; Macrophages, Peritoneal; Microscopy, Fluorescence; Oligopeptides; Rats, Wistar | 2016 |
Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice.
Topics: Animals; Arachidonate 5-Lipoxygenase; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Hydroxyurea; Janus Kinase 2; Leukotriene Antagonists; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Polycythemia Vera; Polymerase Chain Reaction | 2017 |
Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction.
Topics: Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Hydroxyurea; Leukotriene Antagonists; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2017 |
Evaluation of Dual 5-Lipoxygenase/Microsomal Prostaglandin E2 Synthase-1 Inhibitory Effect of Natural and Synthetic Acronychia-Type Isoprenylated Acetophenones.
Topics: Acetophenones; Animals; Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Humans; Hydroxyurea; Inhibitory Concentration 50; Intramolecular Oxidoreductases; Lipoxygenase Inhibitors; Mice; Molecular Structure; Prenylation; Prostaglandin-E Synthases; Rutaceae; Structure-Activity Relationship | 2017 |
Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer's phenotype.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Diet; DNA Methylation; Female; Folic Acid; Folic Acid Deficiency; Homocysteine; Humans; Hydroxyurea; Inflammation; Lipoxygenase; Male; Mice, Transgenic; Phenotype; Phosphorylation; Synapses; tau Proteins; Up-Regulation; Vitamin B Complex; Vitamin B Deficiency | 2017 |
Lack of Long-Term Neurologic Efficacy of Zileuton in Sjögren-Larsson's Syndrome.
Topics: Adolescent; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hydroxyurea; Infant; Lipoxygenase Inhibitors; Male; Outcome Assessment, Health Care; Sjogren-Larsson Syndrome | 2017 |
Effect of the lipoxygenase-inhibitors baicalein and zileuton on the vertebra in ovariectomized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Cancellous Bone; Female; Flavanones; Hydroxyurea; Lipoxygenase Inhibitors; Lumbar Vertebrae; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley | 2017 |
The role of 5-lipoxygenase in Aggregatibacter actinomycetemcomitans-induced alveolar bone loss.
Topics: Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Animals; Arachidonate 5-Lipoxygenase; Cell Differentiation; Cells, Cultured; Hydroxyurea; Interleukin-6; Mice; Osteoclasts; Real-Time Polymerase Chain Reaction; Tumor Necrosis Factor-alpha | 2017 |
New Hydroxycinnamic Acid Esters as Novel 5-Lipoxygenase Inhibitors That Affect Leukotriene Biosynthesis.
Topics: Arachidonate 5-Lipoxygenase; Caffeic Acids; Coumaric Acids; Enzyme Activation; Hydroxyurea; Leukotrienes; Lipoxygenase Inhibitors; Phenylethyl Alcohol; Structure-Activity Relationship | 2017 |
5-LO inhibition ameliorates palmitic acid-induced ER stress, oxidative stress and insulin resistance via AMPK activation in murine myotubes.
Topics: AMP-Activated Protein Kinases; Animals; Arachidonate 5-Lipoxygenase; Cell Line; Endoplasmic Reticulum Stress; Hydroxyurea; Insulin Resistance; Leukotriene B4; Lipoxygenase Inhibitors; Mice; Muscle Fibers, Skeletal; Oxidative Stress; Palmitic Acid; Phosphorylation | 2017 |
Naja sputatrix Venom Preconditioning Attenuates Neuroinflammation in a Rat Model of Surgical Brain Injury via PLA2/5-LOX/LTB4 Cascade Activation.
Topics: Animals; Arachidonate 5-Lipoxygenase; Biomarkers; Brain; Brain Edema; Brain Injuries; Elapid Venoms; Hydroxyurea; Inflammation; Intraoperative Complications; Leukocyte Count; Leukotriene B4; Lipoxygenase Inhibitors; Naja; Phospholipase A2 Inhibitors; Phospholipases A2; Rats; Signal Transduction; Skin; Subcutaneous Tissue; Terpenes | 2017 |
Topics: Animals; Aorta; Arachidonic Acid; Aspirin; Cell Adhesion Molecules; DNA, Bacterial; Endothelial Cells; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Hydroxyurea; Inflammation; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred BALB C; Monocytes; Mutation; Phospholipases A2; Recombinant Proteins; Signal Transduction; Streptococcus pyogenes; THP-1 Cells; Vascular Cell Adhesion Molecule-1 | 2017 |
Androgen-mediated sex bias impairs efficiency of leukotriene biosynthesis inhibitors in males.
Topics: 5-Lipoxygenase-Activating Proteins; Androgens; Animals; Arachidonate 5-Lipoxygenase; Dihydrotestosterone; Female; Humans; Hydroxyurea; Leukocytes; Leukotrienes; Lipoxygenase Inhibitors; Male; Mice; Pyrroles; Rats; Rats, Wistar; Sex Factors; Sulindac; Testosterone | 2017 |
Effect of zileuton on osteoporotic bone and its healing, expression of bone, and brain genes in rats.
Topics: Animals; Brain; Drug Evaluation, Preclinical; Female; Hydroxyurea; Lipoxygenase Inhibitors; Osteoporosis; Ovariectomy; Rats, Sprague-Dawley; Tibia; X-Ray Microtomography | 2018 |
Antidepressant-like effect of zileuton is accompanied by hippocampal neuroinflammation reduction and CREB/BDNF upregulation in lipopolysaccharide-challenged mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cyclic AMP; Depression; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Hydroxyurea; Interleukin-1beta; Lipopolysaccharides; Male; Mice; Signal Transduction; Tumor Necrosis Factor-alpha; Up-Regulation | 2018 |
The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma.
Topics: Asthma; Cell Line; Humans; Hydroxyurea; Leukotrienes; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Quantitative Trait Loci; RNA, Messenger; Signal Transduction | 2018 |
Zileuton alleviates acute cisplatin nephrotoxicity: Inhibition of lipoxygenase pathway favorably modulates the renal oxidative/inflammatory/caspase-3 axis.
Topics: Animals; Caspase 3; Cisplatin; Hydroxyurea; Kidney; Leukotriene B4; Leukotriene D4; Lipoxygenases; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2018 |
The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study.
Topics: Adult; Arachidonate 5-Lipoxygenase; Female; Healthy Volunteers; Humans; Hydroxyurea; Male; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Placebos; Positron-Emission Tomography; Single-Blind Method; Thiazolidinediones; Young Adult | 2018 |
Inhibition of 5-lipoxygenase represses neutrophils activation and activates apoptosis in pancreatic tissues during acute necrotizing pancreatitis.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Biomarkers; Caspase 3; Enzyme Activation; Hydroxyurea; Male; Neutrophil Activation; Neutrophils; Pancreas; Pancreatitis, Acute Necrotizing; Rats, Sprague-Dawley; RNA, Messenger | 2018 |
Antileukotriene therapy by reducing tau phosphorylation improves synaptic integrity and cognition of P301S transgenic mice.
Topics: Animals; Cognition; Disease Models, Animal; Hydroxyurea; Leukotriene Antagonists; Mice; Mice, Transgenic; Phosphorylation; tau Proteins | 2018 |
Learning Impairments, Memory Deficits, and Neuropathology in Aged Tau Transgenic Mice Are Dependent on Leukotrienes Biosynthesis: Role of the cdk5 Kinase Pathway.
Topics: Animals; Behavior, Animal; Brain; Cyclin-Dependent Kinase 5; Hydroxyurea; Leukotriene Antagonists; Leukotrienes; Memory Disorders; Mice; Mice, Transgenic; Phosphorylation; Signal Transduction; Spatial Learning; tau Proteins; Tauopathies | 2019 |
Leukotriene B4 promotes neovascularization and macrophage recruitment in murine wet-type AMD models.
Topics: Animals; Benzopyrans; Carboxylic Acids; Choroidal Neovascularization; Disease Models, Animal; Eye; Eye Injuries; Hydroxyurea; Indoles; Lasers; Leucine; Leukotriene B4; Macrophages; Macular Degeneration; Male; Mice; Mice, Knockout; Neovascularization, Pathologic; Receptors, Leukotriene B4; Signal Transduction | 2018 |
An In Silico Study of the Antioxidant Ability for Two Caffeine Analogs Using Molecular Docking and Quantum Chemical Methods.
Topics: Antioxidants; Caffeine; Catalytic Domain; Computer Simulation; Enzymes; Febuxostat; Fluorouracil; Hydroxyurea; Molecular Docking Simulation; Quantum Theory | 2018 |
Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.
Topics: Antioxidants; Arachidonate 5-Lipoxygenase; Catalytic Domain; Drug Design; Enzyme Assays; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Molecular Docking Simulation; Molecular Structure; Peroxidases; Piperidines; Structure-Activity Relationship | 2019 |
Effect of Zileuton Treatment on Sinonasal Quality of Life in Patients with Aspirin-Exacerbated Respiratory Disease.
Topics: Adult; Aged; Allergens; Anti-Asthmatic Agents; Arachidonate 5-Lipoxygenase; Aspirin; Asthma, Aspirin-Induced; Chronic Disease; Female; Humans; Hydroxyurea; Male; Middle Aged; Quality of Life; Retrospective Studies; Sinusitis; Surveys and Questionnaires; Treatment Outcome | 2019 |
Zileuton, a 5-Lipoxygenase Inhibitor, Exerts Anti-Angiogenic Effect by Inducing Apoptosis of HUVEC via BK Channel Activation.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Human Umbilical Vein Endothelial Cells; Humans; Hydroxyurea; Large-Conductance Calcium-Activated Potassium Channels; Lipoxygenase Inhibitors; Mice; Mice, Inbred C57BL | 2019 |
Zileuton™ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells.
Topics: Animals; Breast Neoplasms; Female; Humans; Hydroxyurea; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Micelles; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Xenograft Model Antitumor Assays | 2020 |
The 5-Lipoxygenase Inhibitor Zileuton Protects Pressure Overload-Induced Cardiac Remodeling via Activating PPAR
Topics: Animals; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Hydroxyurea; Lipoxygenase Inhibitors; Male; Mice; Myocytes, Cardiac; NF-E2-Related Factor 2; PPAR alpha; Rats; Signal Transduction; Ventricular Remodeling | 2019 |
Pharmaceutical analysis combined with in-silico therapeutic and toxicological profiling on zileuton and its impurities to assist in modern drug discovery.
Topics: Arachidonate 5-Lipoxygenase; Chromatography, Liquid; Computer Simulation; Drug Contamination; Drug Discovery; Hydrolysis; Hydroxyurea; Magnetic Resonance Spectroscopy; Molecular Docking Simulation; Molecular Structure; Oxidative Stress; Software; Tandem Mass Spectrometry | 2020 |
Participation of 5-lipoxygenase and LTB4 in liver regeneration after partial hepatectomy.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Proliferation; Cyclin D1; Eicosanoids; Hepatectomy; Hydrogen-Ion Concentration; Hydroxyurea; Leukotriene B4; Leukotrienes; Liver; Liver Regeneration; Macrophages; Male; Neutrophils; NF-kappa B; Rats; Rats, Wistar; Signal Transduction | 2019 |
Zileuton use and phenotypic features in asthma.
Topics: Adult; Aged; Anti-Asthmatic Agents; Asthma; Female; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Lung; Male; Middle Aged; Phenotype; Respiratory Function Tests; Retrospective Studies; Severity of Illness Index | 2020 |
Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Artificial Intelligence; Cells, Cultured; Data Mining; Drug Repositioning; Hydroxyurea; Lipopolysaccharides; Macrophages; Mice; Neural Networks, Computer; NF-E2-Related Factor 2; RAW 264.7 Cells; Semantics; Sequence Analysis, RNA; Signal Transduction | 2020 |
Targeting Neutrophils for Enhanced Cancer Theranostics.
Topics: Cell Line, Tumor; Drug Design; Drug Liberation; Humans; Hydroxyurea; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Neutrophils; Photosensitizing Agents; Serotonin; Tumor Microenvironment | 2020 |
High ability of zileuton ((±)-1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea) to stimulate I
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Line; Delayed Rectifier Potassium Channels; Dose-Response Relationship, Drug; Hippocampus; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Potassium Channels, Calcium-Activated | 2020 |
Leukotrienes, a potential target for Covid-19.
Topics: Acetates; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Betacoronavirus; Coronavirus Infections; COVID-19; Cyclopropanes; Cytokine Release Syndrome; Humans; Hydroxyurea; Immunologic Factors; Indoles; Leukotrienes; Pandemics; Phenylcarbamates; Pneumonia, Viral; Quinolines; SARS-CoV-2; Severity of Illness Index; Sulfides; Sulfonamides; Tosyl Compounds | 2020 |
New Zileuton-Hydroxycinnamic Acid Hybrids: Synthesis and Structure-Activity Relationship towards 5-Lipoxygenase Inhibition.
Topics: Arachidonate 5-Lipoxygenase; Computer Simulation; Coumaric Acids; Drug Evaluation, Preclinical; Free Radical Scavengers; HEK293 Cells; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Molecular Docking Simulation; Neutrophils; Structure-Activity Relationship | 2020 |
5-Lipoxygenase inhibition reduces inflammation and neuronal apoptosis via AKT signaling after subarachnoid hemorrhage in rats.
Topics: Administration, Oral; Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Brain Injuries; Chromones; Disease Models, Animal; Humans; Hydroxyurea; Inflammation; Infusions, Intraventricular; Lipoxygenase Inhibitors; Male; Morpholines; Neurons; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Subarachnoid Hemorrhage | 2021 |
5-LO-derived LTB4 plays a key role in MCP-1 expression in HMGB1-exposed VSMCs via a BLTR1 signaling axis.
Topics: Animals; Aorta; Arachidonate 5-Lipoxygenase; Chemokine CCL2; Fatty Alcohols; Glycols; HMGB1 Protein; Hydroxyurea; Leukotriene B4; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Rats; Rats, Sprague-Dawley; Signal Transduction | 2021 |
ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation.
Topics: Analysis of Variance; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Cell Proliferation; Cell Survival; Disease Progression; Humans; Hydroxyeicosatetraenoic Acids; Hydroxyurea; Lipoxygenase Inhibitors; MAP Kinase Signaling System; Phosphorylation; Stomach Neoplasms; Up-Regulation | 2021 |
Development of polymer-based nanoparticles for zileuton delivery to the lung: PMeOx and PMeOzi surface chemistry reduces interactions with mucins.
Topics: Administration, Inhalation; Bronchi; Bronchial Diseases; Cells, Cultured; Drug Carriers; Drug Delivery Systems; Epithelial Cells; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxyurea; Mucins; Nanoparticles; Polyamines; Polyesters; Polymers | 2021 |
Inhibition of Lipoxygenases Showed No Benefit for the Musculoskeletal System in Estrogen Deficient Rats.
Topics: Animals; Bone Diseases, Metabolic; Estrogens; Female; Flavanones; Hydroxyurea; Lipoxygenase Inhibitors; Lipoxygenases; Musculoskeletal System; Osteoporosis; Rats; Rats, Sprague-Dawley | 2021 |
Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models.
Topics: Animals; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Proliferation; Disease Models, Animal; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Lipoxygenase Inhibitors; Mice; Mice, SCID; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2021 |
5-Lipoxygenase Inhibition Protects Retinal Pigment Epithelium from Sodium Iodate-Induced Ferroptosis and Prevents Retinal Degeneration.
Topics: Animals; Arachidonate 5-Lipoxygenase; Cell Line; Disease Models, Animal; Ferroptosis; Gene Knockdown Techniques; Humans; Hydroxyurea; Iodates; Lipoxygenase Inhibitors; Macular Degeneration; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Protective Agents; Reactive Oxygen Species; Retinal Pigment Epithelium; Signal Transduction; Transfection | 2022 |
Zileuton, a 5-Lipoxygenase Inhibitor, Attenuates Haemolysate-Induced BV-2 Cell Activation by Suppressing the MyD88/NF-κB Pathway.
Topics: Animals; Hydroxyurea; Lipopolysaccharides; Lipoxygenase Inhibitors; Microglia; Myeloid Differentiation Factor 88; NF-kappa B; Signal Transduction; Subarachnoid Hemorrhage | 2022 |
Zileuton Alleviates Radiation-Induced Cutaneous Ulcers via Inhibition of Senescence-Associated Secretory Phenotype in Rodents.
Topics: Animals; Cellular Senescence; Fibroblasts; Hydroxyurea; Phenotype; Rodentia; Senescence-Associated Secretory Phenotype; Ulcer | 2022 |